Front. Genet. Frontiers in Genetics Front. Genet. 1664-8021 Frontiers Media S.A. 10.3389/fgene.2019.00186 Genetics Systematic Review Association of mir-196a-2 rs11614913 and mir-149 rs2292832 Polymorphisms With Risk of Cancer: An Updated Meta-Analysis Choupani Jalal 1 † Nariman-Saleh-Fam Ziba 2 † Saadatian Zahra 3 Ouladsahebmadarek Elaheh 2 Masotti Andrea 4 * Bastami Milad 5 6 * 1Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 2Women's Reproductive Health Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 3Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran 4Research Laboratories, Bambino Gesù Children's Hospital-IRCCS, Rome, Italy 5Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran 6Department of Medical Genetics, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Edited by: Yujing Li, Emory University, United States

Reviewed by: Peter Igaz, Semmelweis University, Hungary; Graziella Curtale, The Scripps Research Institute, United States

 *Correspondence: Andrea Masotti andrea.masotti@opbg.net Milad Bastami bastamim@tbzmed.ac.ir

This article was submitted to RNA, a section of the journal Frontiers in Genetics

†These authors have contributed equally to this work

 15 03 2019 2019 10 186 29 07 2018 19 02 2019 Copyright © 2019 Choupani, Nariman-Saleh-Fam, Saadatian, Ouladsahebmadarek, Masotti and Bastami. 2019 Choupani, Nariman-Saleh-Fam, Saadatian, Ouladsahebmadarek, Masotti and Bastami

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Background: Accumulating evidence suggests that functional dysregulations of miRNAs, especially miR-196a-2 and miR-149, in cancers could be attributed to polymorphisms in miRNA sequences. This study was aimed at clarifying the association of mir-196a-2 rs11614913 and mir-149 rs2292832 with cancer risk by performing an updated meta-analysis of genetic association studies.

Methods: PubMed, Embase, Scopus, and ScienceDirect databases were searched until 9 April 2018 to identify eligible studies. Studies should meet the following criteria to be included in the meta-analysis: evaluation of genetic association between rs11614913 and/or rs2292832 and susceptibility to cancer; A case-control design; Written in English; Availability of sufficient data for estimating odds ratio (OR) and its 95% confidence interval (95%CI). Studies that met the following criteria were excluded: review articles, meta-analysis, abstracts or conference papers; duplicate publications; studies on animals or cell-lines; studies without a case-control design; studies that did not report genotype frequencies. Pooled ORs and 95% CIs were estimated using a total of 111 studies (41,673 cases and 49,570 controls) for mir-196a rs11614913 and 44 studies (15,954 cases and 19,594 controls) for mir-149 rs2292832. Stratified analysis according to quality scores, genotyping method, ethnicity, broad cancer category and cancer type was also performed.

Results: Mir-196a-2 rs11614913 T allele was associated with decreased cancer risk in overall population. The association was only significant in Asians but not Caucasians. In subgroup analysis, significant associations were found in high quality studies, gynecological cancers, ovarian, breast, and hepatocellular cancer. Mir-149 rs2292832 was not associated with cancer risk in overall population and there were no differences between Asians and Caucasians. However, the T allele was associated with a decrease risk of gastrointestinal tract cancers under the heterozygote model and an increased risk of colorectal cancer under the recessive model.

Conclusions: The present meta-analysis suggests that mir-196a-2 rs11614913 may contribute to the risk of cancer especially in Asians. Mir-149 rs2292832 may modulate the risk of gastrointestinal tract cancers especially colorectal cancer. This study had some limitations such as significant heterogeneity in most contrasts, limited number of studies enrolling Africans or Caucasians ancestry and lack of adjustment for covariates and environmental interactions.

 microRNA polymorphism meta-analysis cancer mir-196a-2 mir-149 Introduction

Despite remarkable recent progress in clinical management, diagnosis and treatment, cancer has remained one of the major causes of death worldwide. According to the recent World Health Organization (WHO) report, about one in six deaths were caused by cancer in 2015. It is predicted that cancer-related death will increase up to 13.2 million by 2030 worldwide (Ferlay et al., 2010; Bray et al., 2012). Complex genetic and environmental risk factors and also interactions between these components contribute to the etiopathology of different cancers. Until recent years, much effort has been devoted to link the alteration of protein coding genes to tumorigenesis. However, latest evidence has demonstrated the emerging role of noncoding RNAs in cancer development and, especially, introduced microRNAs (miRNAs) as new players in pathobiology of cancers (Peng and Croce, 2016). MiRNAs are short noncoding functional RNAs that are involved in the regulation of transcriptome (Ha and Kim, 2014). They modulate important cellular processes both in normal physiology and disease state and are involved in almost all cellular processes altered during tumorigenesis (Osada and Takahashi, 2007; Li et al., 2009). Human mir-196a (MIR196A2, HGNC:31568) and mir-149 (MIR149, HGNC: 31536) are well-studied miRNAs that may function either as oncomiRs, by targeting tumor suppressor genes, or as tumor suppressors, by targeting oncogenes, in different conditions (Lu et al., 2016; He J. et al., 2018; Ow et al., 2018). It has been shown that single nucleotide polymorphism (SNP) in miRNA genes, such as hsa-mir-196a-2 rs11614913 and hsa-mir-149 rs2292832, may influence their functions through altering miRNA expression, maturation and/or efficiency of targeting and, thereby, contribute to the risk of cancer (Hu et al., 2008; Hoffman et al., 2009; Tu et al., 2012; Nariman-Saleh-Fam et al., 2016, 2017). Several association studies in a range of populations evaluated the contribution of mir-196a-2 rs11614913 and mir-149 rs2292832 to cancer risk; but results are inconclusive. Therefore, this study was aimed at clarifying the association of mir-196a-2 rs11614913 and mir-149 rs2292832 with cancer risk by performing an updated meta-analysis of genetic association studies.

 Materials and Methods Publication Search

To identify all potentially eligible publications, PubMed, Embase, Scopus and ScienceDirect databases were searched, with respect to specific search tips of each database, using following keywords. (“microRNA 196a2” OR “miRNA-196a2” OR “mir-196a2” OR “mir196a” OR “mir-196a-2” OR “pre-mir-196a” OR “pre-mir196a” OR “196a” OR “rs11614913”) OR (“microRNA 149” OR “miRNA-149” OR “mir-149” OR “mir149” OR “pre-mir-149" OR “pre-mir149” OR “rs2292832”) AND (“single nucleotide polymorphism” OR “SNP” OR “variant” OR “variation” OR “polymorphism” OR “mutation” OR “locus”) AND (“neoplasm” OR “cancer” OR “tumor” OR “carcinoma” OR “sarcoma” OR “lymphoma” OR “adenoma” OR “leukemia” OR “leucemia” OR “malignancy” OR “malignance” OR “malignant” OR “glioma”). Last search was performed on 9 April 2018. References of the relevant literature and review articles were also evaluated to identify all potentially eligible articles. This meta-analysis carried out in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (Liberati et al., 2009).

 Inclusion and Exclusion Criteria

Studies should meet the following criteria to be included in the meta-analysis: (1) evaluation of genetic association between rs11614913 and/or rs2292832 and susceptibility to cancer; (2) a case-control design; (3) Written in English; (4) Availability of sufficient data for estimating odds ratio (OR) and its 95% confidence interval (95%CI). Studies that met the following criteria were excluded: (1) review articles, meta-analysis, abstracts or conference papers; (2) duplicate publications; (3) studies on animals or cell-lines; (4) studies without a case-control design (5) studies that did not report genotype frequencies.

 Data Extraction

Data was extracted from each eligible study and manually checked. Then, items were recorded for each eligible study: the first author, publication year, category of cancer, type of cancer, country, ethnicity, source of controls, genotyping method, number of subjects in the case and the control groups, genotype counts for each SNP in the case and the control groups. A broad cancer category was assigned for each study according to the following scheme: gastrointestinal tract cancers (GI, including gastric, esophageal, colorectal, bladder, pancreatic, or hepatocellular cancers), head and neck squamous cell carcinoma (HNC, including oral, non-oral, and nasopharyngeal cancers), gynecologic cancer (GyC, including endometrial, ovarian, and cervical cancers), hematological malignancies (HM, including leukemia and lymphomas), urogenital cancers (UG, including prostate, renal cell, and bladder cancers), or other cancers.

 Quality Assessment

The quality of each study was assessed using quality assessment criteria for genetic association studies used elsewhere (Thakkinstian et al., 2011; Xue et al., 2015). This score is based on seven items including representativeness of cases, representativeness of controls, ascertainment of cancer case, control selection, genotyping examination, Hardy-Weinberg Equilibrium (HWE) status in controls, and total sample size. Quality scores ranged from 0 (lowest) to 15 (highest). Studies which were scored equal to or less than eight were regarded as low quality, while those with scores of greater than eight were regarded as high quality.

 Statistical Analysis

The Meta package for R was used to perform meta-analysis (Schwarzer, 2007). Association of rs11614913 and rs2292832 with cancer was estimated by calculating pooled ORs and their 95% CIs assuming homozygote, heterozygote, dominant, recessive, and allelic models. Heterogeneity was assessed using the Chi-squared based Q test (Lau et al., 1997). In the presence of a significant heterogeneity (i.e., P-value of Q-test < 0.05 or I2 > 50%), the random effect (RE) model (DerSimonian and Laird, 1986) was used to calculate pooled ORs and 95% CIs. Otherwise, the fixed effect (FE) model was used (Mantel and Haenszel, 1959). Significance of the pooled OR was determined by the Z-test (P < 0.05 was considered significant). In cases of remarkable heterogeneity (i.e., I2 > 50%), the potential sources of heterogeneity across studies was explored using univariate meta-regression and stratified analysis. Moreover, subgroup analyses based on genotyping method, study quality, ethnicities, broad cancer categories, and cancer types were carried out. To assess consistency of results and influence of each study on the pooled OR, sensitivity analysis was done by omitting one study at a time and recalculating summary OR and 95% CI. Publication bias was evaluated by the Begg's rank correlation test of funnel plot asymmetry (Begg and Mazumdar, 1994) the “Trim and Fill” approach was used to correct for asymmetry in cases of significant rank correlation test (Duval and Tweedie, 2000a,b). All P-values were two-sided and P-value < 0.05 was considered statistically significant. All statistical analyses were performed in R (version 3.3.1).

 Dealing With HWD (Departure From Hardy-Weinberg Equilibrium)

Departure from Hardy-Weinberg equilibrium (HWE) may be caused by a range of factors, among which genotyping error is more importantly relevant to the association study context. Currently there is no consensus on the way of handling association studies with the controls not in HWE, but it has been recommended that such studies should not be excluded from meta-analysis (Minelli et al., 2008). However, sensitivity analysis should be performed to evaluate the possible effects of such studies on the pooled estimates (Attia et al., 2003; Thakkinstian et al., 2005; Zintzaras and Lau, 2008; Wang X. B. et al., 2014). In the present meta-analysis, the following approach with regards to HWE-deviated studies was followed. Departure of genotype distributions from HWE (i.e., HWD) in the control group of each study was evaluated using the Chi-squared or the exact goodness of fit test. Meta-analyses, including the overall and subgroup analyses, were performed considering all eligible studies including HWD studies. However, to evaluate possible impacts of HWE-deviated studies, HWD sensitivity analysis was performed by evaluating the influence of excluding these studies on point estimates and identifying the influenced genotype contrasts. In cases that excluding HWD studies altered the result of meta-analysis, ORs of such studies were adjusted for HWE deviation by means of incorporating the HWE-expected genotype counts in the control group as recommended (Trikalinos et al., 2006; Zintzaras et al., 2006; Zintzaras, 2008; Zintzaras and Lau, 2008; Srivastava and Srivastava, 2012) and the HWD-adjusted pooled ORs were calculated in genotype contrasts.

 Results Study Characteristics

The process of selecting eligible studies is depicted in Figure 1. A total of 1,645 articles were found from different sources outlined in materials and methods and screened by reading titles and abstracts. A total of 1,509 articles were excluded in which 577 articles were duplicates, 114 articles were abstracts or conference meetings, 86 articles were meta-analysis, 404 were review articles, 7 articles were not written in English, 26 articles were related to other diseases, 36 articles were related to other genes, or polymorphisms and 259 more articles had either obvious irrelevant study design or irrelevant disease/gene. The full text of the remaining 136 articles were evaluated and 9 more articles were also excluded as they did not have either sufficient data to calculate ORs and 95%CIs (n: 4) or an association study design (n: 5). Finally, a total of 127 eligible articles remained (Horikawa et al., 2008; Yang et al., 2008, 2016; Hoffman et al., 2009; Hu et al., 2009, 2013; Tian et al., 2009; Catucci et al., 2010; Christensen et al., 2010; Dou et al., 2010; Kim et al., 2010, 2012; Kontorovich et al., 2010; Li et al., 2010, 2014; Liu et al., 2010, 2013, 2014; Okubo et al., 2010; Peng et al., 2010; Qi et al., 2010, 2014, 2015; Srivastava et al., 2010, 2017; Wang et al., 2010, 2013, 2016; Akkiz et al., 2011; George et al., 2011; Hong et al., 2011; Jedlinski et al., 2011; Mittal et al., 2011; Vinci et al., 2011, 2013; Zhan et al., 2011; Zhou et al., 2011, 2014; Alshatwi et al., 2012; Chen et al., 2012; Chu et al., 2012, 2014; Hezova et al., 2012; Linhares et al., 2012; Min et al., 2012; Tu et al., 2012; Zhang M. et al., 2012; Zhang M. W. et al., 2012; Zhu et al., 2012; Ahn et al., 2013; Han et al., 2013; Huang et al., 2013, 2017; Lv et al., 2013; Ma et al., 2013; Pavlakis et al., 2013; Umar et al., 2013; Wei et al., 2013, 2014; Zhang et al., 2013; Bansal et al., 2014; Dikeakos et al., 2014; Du et al., 2014; Hao et al., 2014; Kou et al., 2014; Kupcinskas et al., 2014a,b; Omrani et al., 2014; Parlayan et al., 2014; Pu et al., 2014; Qu et al., 2014; Roy et al., 2014; Tong et al., 2014; Wang N. et al., 2014; Wang R. et al., 2014; Wang X. H. et al., 2014; Deng et al., 2015; Dikaiakos et al., 2015; Dong et al., 2015; He et al., 2015; Li T. et al., 2015; Liu, 2015; Li X. et al., 2015; Martin-Guerrero et al., 2015; Nikolić et al., 2015; Pratedrat et al., 2015; Sodhi et al., 2015; Sushma et al., 2015; Yan et al., 2015; Yin et al., 2015, 2016, 2017; Dai et al., 2016; Gu and Tu, 2016; Hashemi et al., 2016; Jiang et al., 2016; Li H. et al., 2016; Li J. et al., 2016; Li M. et al., 2016; Miao et al., 2016; Morales et al., 2016; Ni and Huang, 2016; Peckham-Gregory et al., 2016; Shen et al., 2016; Song et al., 2016; Su et al., 2016; Sun et al., 2016; Toraih et al., 2016a,b; Zhang L. H. et al., 2016; Zhao et al., 2016; Afsharzadeh et al., 2017; Bodal et al., 2017; Cîmpeanu et al., 2017; Poltronieri-Oliveira et al., 2017; Rakmanee et al., 2017; Rogoveanu et al., 2017; Tandon et al., 2017; Zhang E. et al., 2017; Abdel-Hamid et al., 2018; Damodaran et al., 2018; Doulah et al., 2018; He J. et al., 2018; He Y. et al., 2018; Mashayekhi et al., 2018; Minh et al., 2018; Ranjbar et al., 2018). Characteristics of the included studies are tabulated in Tables 1, 2.

Flowchart of the identification of eligible studies for meta-analysis of cancer risk associated with mir-196a-2 rs11614913 and mir-149 rs2292832.

Main characteristics of studies evaluating cancer risk associated with miR-196a-2 rs11614913 C/T which included in the current meta-analysis.

N References Country Ethnicity Genotyping Method Design Cases/Controls Genotype distributiona Cancer Type Quality Score PHWE
Cases Controls
1 Abdel-Hamid et al., 2018 Egypt African PCR-RFLP PB 50/50 21/26/3 24/20/6 HCC 10 0.53
2 Damodaran et al., 2018 India Asian PCR-RFLP HB 100/100 32/51/17 47/36/17 PC 7 0.054
3 Doulah et al., 2018 Iran Asian ARMS-PCR HB 98/100 33/51/14 25/62/13 BC 3 0.015
4 He J. et al., 2018 China Asian TaqMan HB 393/812 94/192/107 183/399/230 NB 11 0.73
5 Mashayekhi et al., 2018 Iran Asian PCR-RFLP HB 353/353 142/169/42 149/158/46 BC 10 0.75
6 Minh et al., 2018 Vietnam Vietnamese HRMA HB 113/127 48/35/30 31/64/32 BC 5 0.95
7 Afsharzadeh et al., 2017 Iran Asian ARMS-PCR Not mentioned 100/150 34/52/14 38/93/19 BC 3 0.002
8 Bodal et al., 2017 India Asian PCR-RFLP HB 95/99 48/47/0 64/35/0 BC 8 0.051
9 Huang et al., 2017 China Asian PCR-RFLP PB 165/284 22/81/62 39/134/111 HCC 9 0.95
10 Poltronieri-Oliveira et al., 2017 Brazil Mixed PCR-RFLP PB 149/246 64/57/28 105/120/21 GC 9 0.12
11 Rakmanee et al., 2017 Thiland Asian PCR-RFLP HB 104/180 48/43/13 49/78/53 ALL 9 0.09
12 Rogoveanu et al., 2017 Romania Caucasian TaqMan HB 142/288 61/63/18 121/128/39 GC 9 0.64
13 Srivastava et al., 2017 India Asian PCR-RFLP HB 184/164 20/93/71 21/81/62 CSCC 1- 0.57
14 Yin et al., 2017 China Asian TaqMan HB 1,003/1,003 252/555/196 221/496/286 LC 1- 0.86
15 Zhang E. et al., 2017 China Asian TaqMan HB 340/340 71/169/100 88/155/97 OC 11 0.12
16 Dai et al., 2016 China Asian Mass-ARRAY HB 560/583 197/265/98 155/284/144 BC 10 0.58
17 Gu and Tu, 2016 China Asian PCR-RFLP HB 186/186 39/96/51 57/98/31 GC 7 0.36
18 Hashemi et al., 2016 Iran Asian t-ARMS-PCR HB 169/182 64/88/17 77/93/12 PC 7 0.029
19 Li M. et al., 2016 China Asian MassARRAY HB 182/182 24/83/75 11/79/92 GC 8 0.33
20 Li J. et al., 2016 China Asian Sequencing Not mentioned 109/105 25/64/20 18/52/35 HCC 8 0.95
21 Miao et al., 2016 China Asian Array (Illumina Infinium1) HB 576/1,550 130/284/162 292/755/503 HNSCC 12 0.80
22 Morales et al., 2016 Chile Mixed TaqMan PB 440/807 192/191/57 342/351/114 BC 12 0.13
23 Ni and Huang, 2016 China Asian PCR-RFLP HB 155/342 32/82/41 66/176/100 OvC 9 0.51
24 Peckham-Gregory et al., 2016 USA Caucasian Allele-specific PCR Array PB 179/529 72/88/19 196/257/76 NHL 13 0.62
25 Shen et al., 2016 China Asian SNaPshot PB 1,400/2,185 295/698/407 392/1121/672 ESCC 10 0.046
26 Song et al., 2016 China Asian PCR-RFLP PB 479/431 121/247/111 86/203/142 OvC 13 0.42
27 Su et al., 2016 China Asian PCR-RFLP HB 245/315 83/128/34 119/158/38 GC 10 0.22
28 Sun et al., 2016 China Asian PCR-RFLP HB 134/227 29/66/39 34/116/77 OvC 7 0.42
29 Toraih et al., 2016b Egypt African TaqMan HB 209/100 84/93/32 55/35/10 Cancer 8 0.30
30 Toraih et al., 2016a Egypt African TaqMan PB 125/150 48/63/14 80/53/17 Cancer 11 0.11
31 Wang et al., 2017 China Asian Mass-ARRAY PB 283/283 73/158/52 65/124/94 BlC 10 0.066
32 Yin et al., 2016 China Asian TaqMan HB 575/608 128/298/149 133/297/178 LC 14 0.70
33 Zhang L. H. et al., 2016 China Asian PCR-RFLP PB 175/302 25/85/65 42/138/122 HCC 9 0.83
34 Zhao et al., 2016 China Asian Sequencing HB 114/114 31/50/33 28/61/25 BC 9 0.53
35 Zhou et al., 2011 China Asian PCR-RFLP HB 226/309 46/123/57 58/169/82 CSCC 12 0.09
36 Deng et al., 2015 China Asian PCR-RFLP PB 159/298 41/66/52 56/166/76 BlC 9 0.048
37 Dikaiakos et al., 2015 Greece Caucasian PCR-RFLP PB 157/299 19/69/69 33/149/117 CRC 10 0.18
38 He et al., 2015 China Asian Mass-ARRAY PB 450/450 81/233/136 93/223/134 BC 11 0.94
39 Li T. et al., 2015 China Asian PCR-RFLP PB 318/320 61/146/111 42/134/144 NHL 13 0.26
40 Liu, 2015 China Asian PCR-RFLP PB 266/266 84/131/51 113/123/30 HCC 12 0.76
41 Liu, 2015 China Asian PCR-RFLP HB 216/100 25/133/58 23/49/28 GyC 5 0.95
42 Martin-Guerrero et al., 2015 Spain Caucasian TaqMan PB 104/345 35/40/29 137/159/49 CLL 9 0.86
43 Nikolić et al., 2015 Serbia Caucasian HRMA PB 351/309 150/161/40 121/147/41 PC 10 0.79
44 Qi et al., 2015 China Asian TaqMan PB 321/290 34/119/168 17/88/185 BC 11 0.18
45 Sodhi et al., 2015 India Asian PCR-RFLP PB 250/255 70/161/19 101/146/8 LC 12 5.46e−7
46 Sushma et al., 2015 India Asian PCR-RFLP PB 100/102 22/10/68 6/15/81 OC 8 0.001
47 Yan et al., 2015 China Asian PCR-RFLP HB 274/328 46/147/81 27/165/136 HCC 9 0.02
48 Yin et al., 2015 China Asian TaqMan HB 258/310 50/141/67 63/150/97 LC 11 0.78
49 Bansal et al., 2014 India Asian PCR-RFLP PB 121/165 68/41/12 85/59/21 BC 9 0.058
50 Chu et al., 2014 Taiwan Asian PCR-RFLP PB 188/337 41/81/66 70/167/100 HCC 12 0.94
51 Dikeakos et al., 2014 Greece Caucasian PCR-RFLP HB 163/480 102/46/15 79/229/172 GC 9 0.9
52 Hao et al., 2014 China Asian PCR-RFLP PB 235/282 77/126/32 67/160/55 HCC 11 0.027
53 Kou et al., 2014 China Asian PCR-RFLP PB 271/532 84/150/37 125/304/103 HCC 9 0.001
54 Kupcinskas et al., 2014b Latvia Caucasian TaqMan HB 363/350 144/184/35 159/145/46 GC 8 0.18
55 Kupcinskas et al., 2014a Latvia Caucasian TaqMan HB 193/427 79/87/27 199/174/54 CRC 8 0.12
56 Li et al., 2014 China Asian TaqMan PB 1,020/1,006 209/489/322 218/518/270 NC 13 0.32
57 Du et al., 2014 China Asian TaqMan PB 1,000/1,022 149/514/337 211/497/314 RCC 13 0.61
58 Omrani et al., 2014 Iran Asian T-ARMS-PCR PB 236/203 218/18/0 178/25/0 BC 11 0.70
59 Parlayan et al., 2014 Japan Asian TaqMan HB 827/524 174/409/244 108/270/146 Cancer 11 0.44
60 Pu et al., 2014 China Asian PCR-RFLP HB 159/511 39/95/25 101/324/86 GC 9 1.7e−9
61 Qi et al., 2014 China Asian HRMA PB 314/406 45/209/60 71/214/121 HCC 12 0.17
62 Qu et al., 2014 China Asian PCR-RFLP PB 381/426 126/207/48 133/211/82 ESCC 13 0.96
63 Roy et al., 2014 India Asian TaqMan HB 451/448 218/187/46 242/168/38 OC 10 0.29
64 Tong et al., 2014 China Asian TaqMan PB 570/673 103/308/159 129/307/237 ALL 14 0.11
65 Wang N. et al., 2014 China Asian PCR-LDR PB 597/597 128/307/162 145/298/154 ESCC 13 0.97
66 Zhou et al., 2014 China Asian PCR-RFLP HB 266/281 93/139/34 66/160/55 HCC 10 0.02
67 Ahn et al., 2013 South Korea Asian PCR-RFLP PB 461/447 100/242/119 87/232/128 GC 12 0.35
68 Han et al., 2013 China Asian TaqMan PB 1,017/1,009 207/505/305 220/485/304 HCC 10 0.33
69 Hu et al., 2013 China Asian Sequencing HB 680/690 185/314/181 138/342/210 Glioma 14 0.98
70 Liu et al., 2013 Taiwan Asian PCR-RFLP NA 315/92 64/147/104 26/36/30 OC 6 0.055
71 Lv et al., 2013 China Asian PCR-RFLP PB 347/531 10/223/114 109/331/91 CRC 10 1.5e−8
72 Ma et al., 2013 China Asian Mass-ARRAY PB 190/187 44/92/54 49/79/59 BC 11 0.047
73 Min et al., 2012 South Korea Asian PCR-RFLP PB 446/502 120/201/125 100/254/148 CRC 12 0.68
74 Pavlakis et al., 2013 Greece Caucasian PCR-RFLP PB 93/122 12/33/48 14/58/50 PNC 10 0.75
75 Umar et al., 2013 India Asian PCR-RFLP PB 289/309 146/121/22 171/122/16 ESCC 12 0.39
76 Vinci et al., 2013 Italy Caucasian HRMA HB 160/178 62/86/12 83/84/11 CRC 9 0.11
77 Wang et al., 2013 China Asian TaqMan HB 1,689/1,946 319/851/519 482/940/524 GC 10 0.14
78 Wei et al., 2013 China Asian Mass-ARRAY HB 367/370 65/196/106 87/170/113 ESCC 12 0.16
79 Zhang et al., 2013 China Asian Mass-ARRAY PB 996/995 214/488/294 165/502/328 HCC 10 0.26
80 Alshatwi et al., 2012 Saudi Arabia Asian TaqMan HB 100/100 35/63/2 46/50/4 BC 4 0.051
81 Chen et al., 2012 China Asian PCR-LDR HB 126/407 27/64/35 94/206/107 CRC 12 0.84
82 Chu et al., 2012 Taiwan Asian PCR-RFLP PB 470/425 57/277/136 87/206/132 OC 11 0.68
83 Hezova et al., 2012 Czech Republic Caucasian TaqMan PB 197/212 82/89/26 87/103/22 CRC 9 0.34
84 Kim et al., 2012 South Korea Asian PCR-RFLP PB 159/201 34/84/41 45/107/49 HCC 11 0.41
85 Linhares et al., 2012 Brazil Mixed TaqMan HB 388/388 94/177/117 127/165/96 BC 7 0.005
86 Zhang M. et al., 2012 China Asian PCR-RFLP PB 248/243 11/89/148 17/93/133 BC 13 0.96
87 Zhu et al., 2012 China Asian TaqMan HB 573/588 140/303/130 121/295/172 CRC 12 0.83
88 Akkiz et al., 2011 Turkey Asian PCR-RFLP HB 185/185 77/86/22 58/87/40 HCC 12 0.56
89 George et al., 2011 India Asian PCR-RFLP PB 159/230 55/101/3 106/114/10 PC 10 0.003
90 Hong et al., 2011 South Korea Asian TaqMan HB 406/428 86/224/96 96/198/134 LC 12 0.18
91 Jedlinski et al., 2011 Australia Caucasian PCR-RFLP PB 187/171 68/86/33 58/82/31 BC 9 0.91
92 Mittal et al., 2011 India Asian PCR-RFLP HB 212/250 76/131/5 109/127/14 BlC 10 0.004
93 Vinci et al., 2011 Italy Caucasian HRMA HB 101/129 35/54/12 58/61/10 LC 9 0.34
94 Zhan et al., 2011 China Asian PCR-RFLP HB 252/543 68/128/56 113/267/163 CRC 11 0.89
95 Catucci et al., 2010 Italy Caucasian TaqMan PB 751/1243 334/330/87 532/550/161 BC 11 0.33
Germany Caucasian TaqMan PB 1,101/1,496 432/512/157 584/696/216 BC 11 0.74
96 Christensen et al., 2010 USA Caucasian TaqMan PB 484/555 182/224/78 188/279/88 HNSCC 14 0.39
97 Dou et al., 2010 China Asian PCR-LDR HB 643/656 111/343/189 143/305/208 Glioma 11 0.13
98 Li et al., 2010 China Asian PCR-RFLP HB 310/222 78/150/82 42/102/78 HCC 9 0.46
99 Liu et al., 2010 USA Caucasian PCR-RFLP HB 1,109/1,130 350/565/194 383/545/202 HNSCC 13 0.77
100 Okubo et al., 2010 Japan Asian PCR-RFLP HB 552/697 105/281/166 124/350/223 GC 11 0.54
101 Peng et al., 2010 China Asian PCR-RFLP HB 213/213 76/94/43 56/107/50 GC 10 0.96
102 Qi et al., 2010 China Asian PCR-LDR PB 361/391 82/179/100 92/197/102 HCC 10 0.92
103 Srivastava et al., 2010 India Asian PCR-RFLP PB 230/230 119/95/16 136/75/19 GBC 12 0.09
104 Wang et al., 2010 China Asian SNaPshot HB 458/489 148/262/48 128/250/111 ESCC 11 0.64
105 Kim et al., 2010 Korea Asian PCR-RFLP PB 654/640 187/305,162 155/300/185 LC 14 0.14
106 Hoffman et al., 2009 USA Caucasian Mass-ARRAY HB 426/466 181/209/36 166/229/71 BC 9 0.63
107 Hu et al., 2009 China Asian PCR-RFLP PB 1,009/1,093 239/483/287 218/517/358 BC 14 0.22
108 Tian et al., 2009 China Asian PCR-RFLP PB 1,058/1,035 253/512/293 209/519/307 LC 14 0.73
109 Horikawa et al., 2008 USA Caucasian Capillary electrophoresis PB 276/277 105/126/45 101/117/59 RCC 11 0.03
110 Yang et al., 2008 USA Caucasian Capillary electrophoresis PB 736/731 255/348/133 257/342/132 BlC 13 0.35

Genotype distributions are sorted as CC/CT/TT.

Genotype distributions are sorted as CC/CT/TT. PB, population-based design; HB, hospital-based design; NC, Not clear; ALL, Acute myeloblastic leukemia; BC, Breast cancer; BlC, Bladder cancer; CLL, Chronic lymphoblastic leukemia; CRC, Colorectal cancer; CSCC, Cervical Squamous Cell Carcinoma; ESCC, Esophageal squamous cell carcinoma; GBC, Gallbladder carcinoma; GC, Gastric cancer; HCC, Hepatocellular carcinoma; HNSCC, Head and neck squamous cell carcinoma; LC, Lung cancer; NB, Neuroblastoma; NC, Nasopharyngeal carcinoma; NHL, non-Hodgkin lymphoma; OC, Oral cancer; OvC, Ovarian cancer; PC, Prostate cancer; PNC, Pancreatic cancer; RCC, Renal cell carcinoma.

Main characteristics of studies evaluating cancer risk associated with miR-149 rs2292832 C/T which included in the current meta-analysis.

N References Country Ethnicity Genotyping method Design Cases/Controls Genotype distributiona Cancer type Quality score PHWE
Cases Controls
1 He J. et al., 2018 China Asian TaqMan HB 380/791 32/62/286 59/172/560 NB 10 2.98e−14
2 Ranjbar et al., 2018 Iran Asian PCR-RFLP PB 73/70 8/14/51 4/24/42 CRC 8 0.92
3 Cîmpeanu et al., 2017 Romania Caucasian TaqMan HB 142/288 70/49/23 126/120/42 GC 10 0.15
4 Tandon et al., 2017 India Asian PCR-RFLP HB 200/200 140/37/23 174/16/10 OC 9 7.96e−12
5 Gu and Tu, 2016 China Asian PCR-RFLP HB 186/186 55/89/42 60/87/39 GC 7 0.54
6 Hashemi et al., 2016 Iran Asian t-ARMS-PCR HB 169/182 77/68/24 101/57/24 PC 6 0.002
7 Jiang et al., 2016 China Asian MassARRAY PB 869/955 65/164/640 66/204/685 GC 12 8.88e−16
8 Li H. et al., 2016 China Asian TaqMan PB 555/395 49/252/254 42/176/177 LC 13 0.92
9 Miao et al., 2016 China Asian Array HB 575/1,548 61/231/283 175/647/726 HNSCC 12 0.10
10 Ni and Huang, 2016 China Asian PCR-RFLP HB 155/342 47/82/26 108/179/55 OvC 9 0.20
11 Su et al., 2016 China Asian PCR-RFLP HB 245/315 108/112/25 149/140/26 GC 10 0.44
12 Yang et al., 2016 China Asian PCR-RFLP PB 30/98 3/16/11 9/49/40 KS 9 0.35
13 Dong et al., 2015 China Asian MassARRAY PB 369/751 63/175/131 91/339/321 PTC 12 0.96
14 He et al., 2015 China Asian Mass-ARRAY PB 450/450 36/183/231 60/188/202 BC 11 0.14
15 Liu, 2015 China Asian PCR-RFLP PB 266/266 91/130/45 108/124/34 HCC 12 0.76/
16 Pratedrat et al., 2015 Thailand Asian TaqMan HB 104/95 11/27/66 9/24/62 HCC 8 0.018
17 Sushma et al., 2015 India Asian PCR-RFLP PB 100/102 72/22/6 90/12/0 OC 9 0.79
18 Yan et al., 2015 China Asian PCR-RFLP HB 274/328 66/133/75 72/156/100 HCC 10 0.50
19 Chu et al., 2014 Taiwan Asian PCR-RFLP PB 188/337 13/36/139 27/64/246 HCC 11 8.9e-10
20 Dikeakos et al., 2014 Greece Caucasian PCR-RFLP HB 163/480 21/73/69 33/198/249 GC 9 0.50
21 Du et al., 2014 China Asian TaqMan PB 355/362 47/163/145 37/148/177 RCC 12 0.52
22 Kou et al., 2014 China Asian PCR-RFLP PB 270/532 113/122/35 202/253/77 HCC 10 0.93
23 Liu et al., 2014 China Asian PCR-RFLP PB 327/327 84/143/100 56/138/133 HCC 11 0.066
24 Pu et al., 2014 China Asian PCR-RFLP HB 187/459 22/31/134 48/103/308 GC 9 8.5e-13
25 Wang R. et al., 2014 China Asian MassARRAY HB 772/717 83/318/371 56/309/352 HCC 9 0.33
26 Wang X. H. et al., 2014 China Asian PCR-RFLP PB 152/304 13/72/67 43/148/113 HCC 11 0.68
27 Wei et al., 2014 China Asian MassARRAY PB 838/1,006 105/354/379 86/424/496 PTC 14 0.77
28 Ahn et al., 2013 South Korea Asian PCR-RFLP PB 461/447 44/176/241 40/187/220 GC 12 0.94
29 Hu et al., 2013 China Asian Sequencing HB 680/690 70/297/313 78/302/310 Glioma 14 0.78
30 Huang et al., 2013 China Asian PCR-RFLP PB 158/242 22/67/69 39/113/90 NPC 11 0.8
31 Lv et al., 2013 China Asian PCR-RFLP PB 347/459 30/64/253 48/103/308 CRC 10 8.5e-13
32 Min et al., 2012 South Korea Asian PCR-RFLP PB 446/502 48/177/221 51/219/232 CRC 12 0.97
33 Vinci et al., 2013 Italy Caucasian HRMA HB 160/178 79/58/23 86/75/17 CRC 9 0.95
34 Chu et al., 2012 Taiwan Asian PCR-RFLP PB 470/425 37/88/345 26/84/315 OC 10 1.1e-7
35 Kim et al., 2012 South Korea Asian PCR-RFLP PB 159/201 14/64/81 21/97/83 HCC 11 0.40
36 Tu et al., 2012 Taiwan Asian PCR-RFLP PB 273/122 20/129/124 21/52/49 HNSCC 7 0.33
37 Zhang M. et al., 2012 China Asian PCR-RFLP PB 245/229 23/102/120 24/113/92 BC 13 0.25
38 Zhang M. W. et al., 2012 China Asian PCR-RFLP PB 443/435 50/190/203 46/202/187 CRC 14 0.48
PB 274/269 41/101/132 35/120/114 GC 14 0.77
39 Vinci et al., 2011 Italy Caucasian HRMA HB 101/129 44/41/16 65/53/11 LC 9 0.89
40 Kontorovich et al., 2010 Israel Asian MassARRAY PB 167/122 87/40/40 53/30/39 Cancer 9 6.5e-8
41 Liu et al., 2010 USA Caucasian PCR-RFLP HB 1,109/1,130 580/441/88 586/445/99 HNSCC 13 0.29
42 Hu et al., 2009 China Asian PCR-RFLP PB 1,009/1,093 450/460/99 482/503/108 BC 14 0.17
43 Tian et al., 2009 China Asian PCR-RFLP PB 1,058/1,035 123/472/463 112/453/470 LC 14 0.89

Genotype distributions are sorted as CC/CT/TT.

Genotype distributions are sorted as CC/CT/TT. PB, population-based design; HB, hospital-based design; BC, Breast cancer; CRC, Colorectal cancer; GC, Gastric cancer; HCC, Hepatocellular carcinoma; HNSCC, Head and neck squamous cell carcinoma; LC, Lung cancer; NB, Neuroblastoma; NC, Nasopharyngeal carcinoma; NSCLC, non-Small cell lung carcinoma; OC, Oral cancer; OvC, Ovarian cancer; PC, Prostate cancer; PTC, Papillary thyroid carcinoma; RCC, Renal cell carcinoma; KS, Kaposi sarcoma.

A total of 110 articles which included 111 studies (41,673 cases and 49,570 controls) evaluated the association of miR-196a-2 rs11614913 and cancer risk (Table 1). The article by Catucci et al. included two studies on separate populations (Catucci et al., 2010). In a study on head and neck carcinoma the genotype frequencies were not reported in the paper and data were retrieved by contacting the authors (Christensen et al., 2010). The final meta-analysis of mir-196a-2 rs11614913 and cancer risk included 111 studies (including 41,673 patients and 49,570 controls), among which 93 were scored greater than eight in the quality assessment and regarded as high quality studies. In 93 out of 111 studies, the genotype distribution of rs11614913 in the control group was concordant with HWE. Mir-196a-2 rs11614913 were genotype using a range of techniques with the most common being PCR-RFLP (n = 53). With regard to the ethnicity, 85 studies were performed in Asians, 20 were performed in Caucasians and the remaining six studies were included either Africans or individuals from different ancestries (mixed ancestry). In four studies the patients were subgrouped into multiple cancer types. Namely, Liu evaluated both ovarian and endometrial cancers (Liu, 2015), Parlayan evaluated gastric, lung, colorectal, prostate, and acute leukemia (Parlayan et al., 2014), Toraih studied both GI and non-GI cancers in a study (Toraih et al., 2016b) and hepatic and renal cancers in another study (Toraih et al., 2016a). For these studies genotype distribution of all patients were used to calculate point estimates in the overall analysis. However, in subgroup analysis, as these studies were assigned to more than one subgroup, the genotype distribution of patients with the relevant cancer category/type was used for pooling data. When studies were subgrouped according to the broad cancer category, there were 49 gastrointestinal tract cancers (GI), nine head and neck squamous cell carcinoma (HNSCC), six gynecologic cancers (GyC), six hematological malignancies (HM), 12 urogenital cancers (UG), and 34 other cancers. When studies subgrouped according to cancer type, there were 21 breast cancer (BC), 18 hepatocellular carcinoma (HCC), 13 gastric cancer (GC), ten colorectal cancer (CRC), nine lung cancer (LC), four bladder cancer (BlC), five prostate cancer (PC), six oral carcinoma (OC), four ovarian cancer (OvC), six esophageal cancer (ESCC), and 22 other cancer types.

Moreover, 43 articles comprising 44 studies (15,954 cases and 19,594 controls) evaluated the association of mir-149 rs2292832 and cancer risk (Table 2), among which 39 studies were evaluated as being high quality (quality score > 8). The genotype distribution of rs2292832 in the control groups of 34 studies were in agreement with HWE. The main genotyping technique was PCR-RFLP (29 studies). Most studies (n: 39) were performed in Asian populations and only few studies (n: 5) had focused on Caucasians. According to the broad cancer category, there were 22 GI studies, seven HNC studies and 15 studies on other cancer types. When studies were subgrouped by cancer type, there were four studies on BC, nine studies on HCC, eight studies on GC, five studies on CRC, three studies on LC and 15 studies on other types of cancer.

 Quantitative Synthesis Association of mir-196a2 rs11614913 and Cancer Risk

Statistically significant associations between mir-196a2 rs11614913 and cancer risk were observed assuming the homozygote (TT vs. CC, ORRE [95% CI]: 0.88 [0.79–0.98], P: 0.027) and the recessive (TT vs. CC+CT, ORRE [95% CI]: 0.89 [0.83–0.95], P: 0.001) models (Table 3). Mir-196a-2 rs11614913 was not associated with cancer risk in the heterozygote and dominant models and there was a non-significant borderline association in the allele contrast (Table 3). Supplementary Figure S1 shows the forest plots of association of mir-196a-2 rs11614913 and cancer risk in five models. The results of subgroup analysis for mir-196a-2 rs11614913 are shown in Table 4. Decreased risk of cancer was found in high quality studies under the homozygote (TT vs. CC, ORRE [95% CI]: 0.87 [0.77–0.97], P: 0.017), the recessive (TT vs. CC+CT, ORRE [95% CI]: 0.88 [0.81–0.95], P: 0.001) and the allele contrasts (T vs. C, ORRE [95% CI]: 0.93 [0.88–0.99], P: 0.020). In subgroup analysis by genotyping method, the only significant association was observed under the recessive model for studies which used a method other than PCR-RFLP (TT vs. CC+CT, ORRE [95% CI]: 0.89 [0.82–0.96], P: 0.007). When sub-grouped by ethnicity, decreased risks of cancer under the homozygote (TT vs. CC, ORRE [95% CI]: 0.86 [0.77–0.97], P: 0.016), the recessive (TT vs. CC+CT, ORRE [95% CI]: 0.87 [0.81–0.93] P: 0.0004) and the allelic (T vs. C, ORRE [95% CI]: 0.93 [0.89–0.98], P: 0.015) models were found only in Asians but not in Caucasians or the African/mixed ancestry subgroups (Table 4, Figure 2). Subgrouping by broad cancer categories indicated that mir-196a-2 rs11614913 was associated by a decreased risk of gynecologic cancer (GyC) assuming the recessive model (TT vs. CC+CT, ORFE [95% CI]: 0.80 [0.68–0.95], P: 0.010) and the allelic contrast (T vs. C, ORFE [95% CI]: 0.88 [0.79–0.98], P: 0.021) (Figure 3). No significant findings were observed for gastrointestinal, head and neck, hematological or urogenital cancers (Table 4). Supplementary Figure S2 presents the forest plots for subgroups according to the broad cancer categories. Further subgrouping by cancer type revealed significant association of mir-196a-2 rs11614913 with hepatocellular carcinoma (Figure 4) under the homozygote model (TT vs. CC, ORRE [95% CI]: 0.73[0.57–0.94], P: 0.017), the recessive model (TT vs. CC+CT, ORRE [95% CI]: 0.79 [0.66–0.95], P: 0.017) and the allele contrast (T vs. C, ORFE [95% CI]: 0.88 [0.78–0.98], P: 0.030), and with ovarian cancer (Figure 5) under the recessive model (TT vs. CC+CT, ORFE [95% CI]: 0.73[0.60–0.90], P: 0.003). Supplementary Figure S3 presents the forest plots for subgroups according to cancer type.

Summary of the results of meta-analysis of cancer risk associated with miR-196a-2 rs11614913 and miR-149 rs2292832.

Genetic models na Cases/controls ORb (95% CI) Pc PHetd I2 Pblase
miR-196a2 rs11614913
Homozygote (TT vs. CC) 109 41,342/49,268 0.88 (0.79–0.98) 0.027 <0.0001 77.1% 0.370
Heterozygote (CT vs. CC) 111 41,673/49,570 1.00 (0.92–1.07) 0.960 <0.0001 70.4% 0.832
Dominant (TT+CT vs. CC) 111 41,673/49,570 0.96 (0.89–1.04) 0.429 <0.0001 76.8% 0.666
Recessive (TT vs. CT+CC) 109 41,342/49,268 0.89 (0.83–0.95) 0.001 <0.0001 68.6% 0.496
Allelic (T vs. C) 111 41,673/49,570 0.95 (0.90–1.00) 0.051 <0.0001 78.9% 0.148
miR-149 rs2292832
Homozygotef (TT vs. CC) 44 15,954/19,594 0.89 (0.77–1.02) 0.119 <0.0001 64.2 0.004
Heterozygote (CT vs. CC) 44 15,954/19,594 0.96 (0.87–1.05) 0.427 0.008 37.1 0.478
Dominant (CT+TT vs. CC) 44 15,954/19,594 1.00 (0.90–1.11) 0.955 <0.0001 53.5 0.175
Recessivef (TT vs. CC+CT) 44 15,954/19,594 1.00 (0.92–1.08) 0.907 <0.0001 48.6 0.045
Allelic (T vs. C)f 44 15,954/19,594 0.96 (0.88–1.04) 0.358 <0.0001 73.6 0.026

Number of studies in each contrast.

Pooled OR and 95% CI (Random-effect model).

P-value of the Z-test.

P-value of the Q-test.

P-value of the Begg's test.

For these models (homozygote, recessive, and allelic comparisons of rs2292832) “trim and fill” adjusted results are shown (consult with Supplementary Figure S4 for forest plots and Supplementary Figure S11 for funnel plots of these models).

Significant associations are shown in boldface.

Meta-analysis of miR-196a-2 rs11614913 and cancer risk.

Homozygote (TT vs. CC) Heterozygote (CT vs. CC) Dominant (TT+CT vs. CC) Recessive (TT vs. CT+CC) Allelic (T vs. C)
Groups Cases/Controlsa ORb (95% CI) Pc I2 ORb (95% CI) Pc I2 ORb (95% CI) Pc I2 ORb (95% CI) Pc I2 ORb (95% CI) Pc I2
All studies 41,673/49,570 0.88 (0.79–0.98) <1e−4 77.1 1.00 (0.93–1.08) <1e−4 70.4 0.97 (0.89–1.05) <1e−4 76.8 0.89 (0.83–0.96) <1e−4 68.6 0.95 (0.90–1.00) <1e−4 78.9
Controls in HWE d 36,620/42,501 0.88 (0.80–0.98) <1e−4 74.6 1.00 (0.93–1.08) <1e−4 66.3 0.97 (0.89–1.04) <1e−4 74.3 0.88 (0.82–0.95) <1e−4 67.7 0.94 (0.89–0.99) <1e−4 77.3
QUALITY
High (>8) 38,503/46,453 0.87 (0.77–0.97) <1e−4 78.1 0.98 (0.91–1.06) <1e−4 69.6 0.94 (0.87–1.03) <1e−4 76.7 0.88 (0.81–0.95) <1e−4 70.9 0.93 (0.88–0.99) <1e−4 79.7
Low (≤8) 3170/3117 098 (0.70–1.38) <1e−4 68.3 1.09 (0.80–1.48) <1e−4 71.9 1.07 (0.80–1.44) <1e−4 74 0.97 (0.79–1.18) 0.025 44.5 1.03 (0.87–1.22) <1e−4 71
GENOTYPING
PCR–RFLP 15,282/18,081 0.85 (0.69–1.04) <1e−4 81.4 0.96 (0.83–1.11) <1e−4 77.8 0.93 (0.80–1.09) <1e−4 82.9 0.89 (0.78–1.00) <1e−4 71.1 0.93 (0.85–1.02) <1e−4 84
Others 26,391/31,489 0.91 (0.82–1.01) <1e−4 70.3 1.03 (0.96–1.11) <1e−4 57.2 1.00 (0.92–1.07) <1e−4 64.8 0.89 (0.82–0.96) <1e−4 66.5 0.96 (0.91–1.01) <1e−4 70.7
ETHNICITIES
Asian 33,039/38,092 0.86 (0.77–0.97) <1e−4 76.4 1.0 (0.92–1.09) <1e−4 68.3 0.96 (0.88–1.05) <1e−4 74.1 0.87 (0.81–0.93) <1e−4 68.2 0.93 (0.89–0.98) <1e−4 76.4
Caucasian 7273/9737 0.86 (0.63–1.18) <1e−4 81.1 0.92 (0.75–1.13) <1e−4 78.3 0.91 (0.72–1.15) <1e−4 85.1 0.92 (0.73–1.15) <1e−4 71.2 0.94 (0.78–1.13) 0.00 86.5
Africans/mixed 1361/1741 1.40 (0.89–2.21) 0.058 53.1 1.27 (0.87–1.86) 0.01 63.1 1.31 (0.95–1.80) 0.02 60.5 1.24 (0.77–2.0) 0.05 54.3 1.21 (0.99–1.49) 0.047 55.3
CANCER CATEGORIES
GI 16,537/21,226 0.87 (0.71–1.06) <1e−4 83.7 0.96 (0.84–1.10) <1e−4 76.8 0.93 (0.80–1.08) <1e−4 82.9 0.90 (0.79–1.02) <1e−4 76.1 0.94 (0.85–1.03) <1e−4 85
HNC 4,865/5,648 1.05 (0.76–1.46) 0.001 68.9 1.10 (0.79–1.54) <1e−4 75 1.08 (0.78–1.49) <1e−4 76.2 0.99 (0.90–1.09) 0.085 42.3 1.01 (0.85–1.21) 5e−4 71.2
GyC 1,394/1,573 0.85 (0.53–1.36) 0.042 56.6 1.02 (0.66–1.58) 0.061 52.5 0.96 (0.61–1.50) 0.030 59.5 0.80 (0.68–0.95) 0.346 10.8 0.88 (0.79–0.98) 0.089 47.6
HM 1,347/2,571 0.71 (0.34–1.49) 1e−4 80.4 0.91 (0.77–1.09) 0.071 50.7 0.79 (0.52–1.19) 0.008 67.5 0.80 (0.42–1.51) 0.00 80.2 0.83 (0.57–1.21) 0.00 80.5
UG 3,599/4,356 0.98 (0.74–1.30) 0.002 61.5 1.19 (0.96–1.48) 0.003 60.5 1.15 (0.94–1.42) 0.002 61.3 0.91 (0.70–1.19) 0.001 63.8 1.047 (0.91–1.19) 0.002 61.5
Others 13,710/16,018 0.86 (0.76–0.98) <1e−4 57.2 0.98 (0.88–1.10) <1e−4 56.7 0.95 (0.85–1.06) <1e−4 62.4 0.87 (0.79–0.95) 0.003 44.6 0.94 (0.87–1.00) <1e−4 62.3
CANCER TYPES
BC e 7,401/8,828 0.85 (0.71–1.01) 0.001 56.4 0.93 (0.81–1.08) 0.002 53.3 0.91 (0.78–1.06) 2e−4 60.8 0.89 (0.79–1.01) 0.024 43 0.93 (0.84–1.02) <1e−4 62.7
HCCe 5,401/6,326 0.73 (0.57–0.94) <1e−4 69.5 0.92 (0.78–1.09) 0.002 55.2 0.87 (0.73–1.04) <1e−4 64.7 0.79 (0.66–0.95) 2e−4 63.2 0.88 (0.78–0.98) <1e−4 68.8
GC 4,664/6,385 0.80 (0.47–1.36) <1e−4 90.3 0.81 (0.56; 1.15) <1e−4 88.6 0.80 (0.53–1.20) <1e−4 92.1 0.91 (0.65–1.29) <1e−4 81.5 0.88 (0.66–1.17) <1e−4 92.4
CRCe 2,567/4,211 1.21 (0.65–2.27) <1e−4 87.6 1.12 (0.71–1.75) <1e−4 81.1 1.13 (0.70–1.85) <1e−4 84.7 1.08 (0.83–1.42) <1e−4 78.6 1.06 (0.86–1.29) <1e−4 86.4
LC e 4,453/4,932 0.86 (0.63–1.17) 0.009 60.2 1.01 (0.91–1.12) 0.057 46.9 1.00 (0.82–1.21) 0.015 57.7 0.82 (0.65–1.03) 0.012 59 0.93 (0.81–1.08) 0.004 64.5
BlC 1,390/1,562 0.75 (0.41–1.39) 0.060 59.3 1.01 (0.53–1.89) 0.017 70.4 0.97 (0.62–1.52) 0.088 54 0.77 (0.30–1.97) 3e−4 84.3 0.94 (0.68–1.29) 0.036 64.7
PC 868/1,345 1.01 (0.74–1.39) 0.396 1.8 1.27 (0.83–1.95) 0.057 56.4 1.23 (0.83–1.83) 0.069 54 0.94 (0.71–1.24) 0.485 0 1.06 (0.93–1.22) 0.241 27.1
OC 2,138/2,957 0.98 (0.49–1.95) <1e−4 81.6 1.14 (0.57–2.29) <1e−4 82.3 1.07 (0.53–2.12) <1e−4 85 0.87 (0.76–1.00) 0.189 32.8 0.96 (0.66–1.40) <1e−4 82
OvC 843/1,100 0.81 (0.28–2.37) 0.023 68.4 1.03 (0.38–2.78) 0.029 66.6 0.95 (0.34–2.63) 0.017 70.4 0.73 (0.60–0.90) 0.332 12.1 0.88 (0.58–1.32) 0.050 61.6
ESCC 3,492/4,376 0.85 (0.49–1.47) <1e−4 82.4 1.04 (0.83–1.31) 0.039 57.2 0.99 (0.76; 1.29) 0.008 67.8 0.81 (0.51–1.28) <1e−4 81.3 0.94 (0.76–1.16) 6e−4 76.8
Others 8,214/11,444 0.98 (0.80–1.20) <1e−4 68.5 1.05 (0.91–1.22) <1e−4 61.5 1.03 (0.88–1.21) <1e−4 68.3 0.96 (0.83–1.11) <1e−4 61.7 1.00 (0.89–1.11) <1e−4 72

The overall, HWD-sensitivity and subgroup analyses.

n represents number of cases and controls in each group.

Pooled ORs and 95% confidence intervals.

P-value of the heterogeneity test.

Meta-analysis of all studies excluding those with the control group not in HWE.

These subgroups were found to be influenced by departure from HWE. Please consult with the Supplementary Table S2 for details on HWD sensitivity and adjustments.

GI, cancers of digestive system; HNC, Head and neck carcinoma; GyC, Gynecologic cancers; HM, Hematological malignancies; UG, Urogenital cancers; BC, breast cancer; HCC, Hepatocellular cancer; GC, gastric cancer; CRC, colorectal cancer; LC, lung cancer; BlC, bladder cancer; PC, prostate cancer; OC, Oral cancer; OvC, ovarian cancer; ESCC, esophageal squamous cell carcinoma.

Significant associations are shown in boldface.

Forest plot of cancer risk associated with mir-196a-2 rs11614913 in the Asian subgroup (Allele contrast T vs. C). The plot is designed in a side-by-side mode to represent 85 studies in the Asian subgroup. The result of meta-analysis is shown beneath the second column.

Forest plot of cancer risk associated with mir-196a-2 rs11614913 in the gynecological cancers subgroup. From left to right: recessive (TT vs. CT+CC), allelic (T vs. C), and homozygote (TT vs. CC) contrast.

Forest plot of cancer risk associated with mir-196a-2 rs11614913 in the hepatocellular cancer subgroup. From left to right: recessive (TT vs. CT+CC), allelic (T vs. C), and homozygote (TT vs. CC) contrast.

Forest plot of cancer risk associated with mir-196a-2 rs11614913 in the ovarian cancer subgroup. Top left: homozygote (TT vs. CC) contrast; Top right: heterozygote comparison (CT vs. CC); Bottom left: dominant comparison (CT+TT vs. CC); Bottom right: recessive comparison (TT vs. CT+CC).

HWD sensitivity analysis (i.e., excluding studies with controls deviated from HWE) revealed stable results in the overall analysis under the homozygote, heterozygote, dominant, and recessive models (Table 4). However, excluding HWD studies made the borderline allele contrast statistically significant (Table 4). Moreover, excluding HWE violating studies had no dramatic effects on subgroup meta-analyses using quality of studies, genotyping methods, the ethnicity and the broad cancer category (Supplementary Table S1). In meta-analysis subgrouped by cancer type, the results were also stable for gastric, bladder, oral, ovarian, prostate, and esophageal cancer subgroups after excluding HWD studies (Supplementary Table S1). However, excluding such studies altered the results for the breast, hepatocellular, colorectal, and lung cancer subgroups. Therefore, for these subgroups, pooled ORs were estimated to account for departures from HWE (denoted as HWD-adjusted ORs) (Supplementary Table S2). When corrected for HWD, mir-196a-2 rs11614913 was found to be significantly associated with breast cancer under the homozygote (TT vs. CC, HWD-adjusted ORRE [95% CI]: 0.75 [0.61–0.93], P: 0.011) and recessive (TT vs. CC+CT, HWD-adjusted ORRE [95% CI]: 0.84 [0.71–0.98], P: 0.030) models (Figure 6). The association with hepatocellular cancer under the homozygote and the recessive models was remained significant after adjustment for HWD (TT vs. CC, HWD-adjusted ORRE [95% CI]: 0.69 [0.53–0.91], P: 0.011 and TT vs. CC+CT, HWD-adjusted ORRE [95% CI]: 0.72 [0.57–0.90], P: 0.008). Furthermore, adjustment for HWD confirmed that mir-196a-2 rs11614913 is not associated with colorectal or lung cancer assuming any genetic model (Supplementary Table S2).

Forest plot of the original and HWD-adjusted meta-analysis of breast cancer risk and mir-196a-2 rs11614913 under the recessive (TT vs. CT+CC) and homozygote (TT vs. CC) models. Red boxes represent HWD-adjusted log ORs and 95%CIs of studies with HWE-deviated controls (i.e., Linhares et al., 2012; Ma et al., 2013; Afsharzadeh et al., 2017; Doulah et al., 2018). The blue and red diamonds represent the estimated pooled effects of the original and HWD-adjusted meta-analysis, respectively.

 Association of mir-149 rs2292832 and Cancer Risk

The overall analysis showed no significant association with cancer risk under any genetic model (Table 3). Supplementary Figure S4 shows the forest plots for the association of mir-149 rs2292832 and cancer risk under different genetic models. However, in subgroup analyses (Table 5) significant association of rs2292832 with cancer risk was observed in studies which used a genotyping method other than PCR-RFLP (CT vs. CC, ORFE [95% CI]: 0.88 [0.79–0.98], P: 0.025). When subgrouped by broad cancer category, a decreased risk of gastrointestinal tract cancers was found in the heterozygote model (Figure 7A, CT vs. CC, ORFE [95% CI]: 0.87 [0.79–0.97], P: 0.011). Subgrouping by cancer type, however, revealed an increased risk of colorectal cancer for individuals carrying TT genotype compared to those who carry at least one C allele (Figure 7B, TT vs. CT+CC, ORFE [95% CI]: 1.21 [1.04–1.40], P: 0.011). No significant association was observed for other comparisons (Table 5). Supplementary Figures S5, S6 show the forest plots for subgroup analysis according to the broad cancer category and cancer type, respectively. Sensitivity analysis revealed that HWD studies had no significant effect on point estimates in the overall meta-analysis of mir-149 rs2292832 and cancer risk, and still no significant association was observed in overall analysis (Table 5). Moreover, most subgroup analyses were also stable after removing HWD studies (Supplementary Table S3). However, removing studies with HWD controls influenced comparisons in three subgroups: (i) non-PCR-RFLP subgroup (heterozygote model); (ii) the breast cancer subgroup (recessive model); (iii) the colorectal cancer subgroup (recessive model). Therefore, for these subgroups, HWE-expected genotype distributions in controls were used for pooling ORs (denoted as HWD-adjusted OR) (Supplementary Table S4). Adjusting for HWD in these subgroups confirmed the results of original analyses and showed that rs2292832 is associated with cancer risk in non-RFLP subgroup under the heterozygote model (Figure 8, CT vs. CC, HWD-adjusted ORRE [95% CI]: 0.68 [0.48–0.98], P: 0.040) and with colorectal cancer risk under the recessive model (TT vs. CT+CC, HWD-adjusted ORFE [95% CI]: 1.29 [1.11–1.50], P: 0.0007). No association with breast cancer risk was identified after adjusting for HWD (Supplementary Table S4).

Meta-analysis of miR-149 rs2292832 and cancer risk.

Homozygote (TT vs. CC) Heterozygote (CT vs. CC) Dominant (TT+CT vs. CC) Recessive (TT vs. CT+CC) Allelic (T vs. C)
Groups Cases/Controlsa ORb (95% CI) Pc I2 ORb (95% CI) Pc I2 ORb (95% CI) Pc I2 ORb (95% CI) Pc I2 ORb (95% CI) Pc I2
All studies 15,954/19,594 0.89 (0.77–1.02) <1e−4 64.2 0.96 (0.87–1.05) 0.008 37.1 1.00 (0.90– 1.11) <1e−4 53.5 1.00 (0.92–1.08) <1e−4 48.6 0.96 (0.88–1.04) <1e−4 73.6
Controls in HWEd 12,873/15,569 0.88 (0.75–1.04) <1e−4 67 0.95 (0.89–1.02) 0.054 29.7 0.98 (0.87–1.09) 4e−4 50.8 0.98 (0.89–1.07) <1e−4 51.3 095 (0.87–1.03) <1e−4 70.8
QUALITY
High (>8) 15,149/18,939 0.98 (0.87–1.11) <1e−4 52.8 0.94 (0.88–1.00) 0.060 27.4 0.97 (0.88–1.08) 1e−4 51.3 1.04 (0.96–1.13) 7e−4 47.3 1.02 (0.95–1.10) <1e−4 66.3
Low (≤8) 805/655 1.32 (1.83–1.34) 0.183 35.7 1.25 (0.55–2.87) 0.043 59.3 1.31 (0.69– 2.48) 0.087 50.7 1.15 (0.90–1.46) 0.84 0 1.19 (0.98–1.4) 0.599 0f
GENOTYPING
PCR–RFLP 9,437/11,117 1.05 (0.90–1.22) 0.003 46.6 1.01 (0.88–1.14) 0.016 39.5 1.06 (0.92–1.22) 3e−4 54.5 1.08 (0.98–1.19) 0.028 36.3 1.08 (0.98–1.18) <1e−4 64.5
Otherse 6,517/8,477 0.94 (0.76–1.16) 9e−4 61.6 0.88 (0.79–0.98) 0.178 25 0.911 (0.77–1.06) 0.018 48.3 1.0 (0.88–1.13) 0.011 51.4 0.97 (0.88–1.08) 6e−4 62.8
ETHNICITIES
Asian 14,279/17,389 1.01 (0.89–1.15) 0.0001 51.9 0.97 (0.88–1.08) 0.006 40 0.97 (0.88–1.08) 0.006 40 1.05 (0.98–1.13) 0.005 40.6 1.05 (0.97–1.13) <1e−4 65.1
Caucasians 1,675/2,205 0.98 (0.48–1.96) 0.022 64.9 0.93 (0.80–1.07) 0.30 16.5 0.94 (0.82–1.08) 0.13 43.5 1.04 (0.62–1.72) 0.052 57.4 0.95 (0.72–1.27) 0.049 57.9
CANCER CATEGORIES
GI 6,508/8,150 0.96 (0.83–1.12) 0.043 36.9 0.87 (0.79–0.97) 0.57 0 0.92 (0.84–1.01) 0.206 19.2 1.07 (0.99–1.15) 0.079 31.5 1.01 (0.94–1.10) 0.010 46
HNC 2,885/3,769 1.35 (0.76–2.38) 0.003 68.6 1.34 (0.82–2.19) 0.001 72.2 1.45 (0.86–2.42) <1e−4 80.3 1.10 (0.97–1.24) 0.096 44.2 1.30 (0.87–1.94) <1e−4 82.8
Others 6,561/7,675 0.96 (0.78–1.19) 0.001 59.5 0.97 (0.88–1.06) 0.126 30.4 0.98 (0.83–1.15) 0.010 51.9 0.99 (0.87–1.13) 0.011 51.5 0.99 (0.89–1.11) 2e−4 65.5
CANCER TYPES
BCe 1,871/1,894 1.12 (0.53–2.36) 0.014 71.6 1.02 (0.87–1.19) 0.192 36.7 1.07 (0.59–1.93) 0.031 65.9 1.10 (0.68–1.77) 0.063 58.8 1.05 (0.69–1.60) 0.005 76.4
HCC 2,512/3,107 0.95 (0.68–1.34) 0.008 61 0.91 (0.78–1.06) 0.285 17.7 0.93 (0.72–1.20) 0.039 50.6 0.97 (0.86–1.09) 0.049 48.5 0.99 (0.83–1.17) 0.003 65.6
GC 2,527/3,399 0.95 (0.79–1.14) 0.323 13.6 0.85 (0.72–1.00) 0.493 0 0.92 (0.79–1.07) 0.397 4.2 1.08 (0.96–1.22) 0.319 14.2 1.01 (0.93–1.10) 0.194 29.2
CRCe 1,469/1,644 1.10 (0.86–1.40) 0.671 0 0.85 (0.67–1.07) 0.615 0 0.97 (0.78–1.20) 0.704 0 1.21 (1.04–1.40) 0.748 0 1.10 (0.98–1.23) 0.801 0
LC 1,714/1,559 1.04 (0.8246–1.31) 0.116 53.5 1.03 (0.83–1.29) 0.602 0 1.04 (0.84–1.29) 0.351 4.3 0.98 (0.85–1.13) 0.175 42.4 1.04 (0.70–1.52) 0.157 45.8
Others 5,861/7,991 1.02 (0.77–1.34) 2e−4 65.2 1.071 (0.84–1.36) 5e−4 63.5 1.10 (0.85–1.44) <1e−4 73.5 1.00 (0.86–1.16) 0.012 50.7 1.07 (0.89–1.29) <1e−4 77.9

The overall, HWD-sensitivity and subgroup analyses.

n represents number of cases and controls in each group.

Pooled ORs and 95% confidence intervals.

P-value of the heterogeneity test.

Meta-analysis of all studies excluding those with the control group not in HWE.

These subgroups were found to be influenced by departure from HWE. Please refer to the Supplementary Table S4 for details on HWD sensitivity and adjustment analysis for these subgroups.

Although the point estimate of I2 was zero for the allele contrast in the low quality subgroup, the random effect model was used based on the 95%CI of I2 (0–69.8%) and small number of studies.

GI, Gastrointestinal tract cancers; HNC, Head and neck cancers; BC, Breast cancer; HCC, Hepatocellular cancers; GC, Gastric cancer; CRC, Colorectal cancer; LC, Lung cancer.

Significant associations are shown in boldface.

Forest plots of cancer risk associated with mir-149 rs2292832; (A) In the gastrointestinal cancers subgroup assuming the heterozygote model (CT vs. CC). (B) In the colorectal cancer subgroup assuming the recessive model (TT vs. CT+CC). The red box shows the HWD-adjusted log OR (95%CI) for the study by Lv et al. (2013). The blue and red diamonds represent the estimated pooled effect of the original and HWD-adjusted meta-analysis.

Forest plot of the original (Left) and HWD-adjusted (Right) meta-analysis of cancer risk associated with mir-149 rs2292832 in subgroup of studies which used a non-RFLP genotyping method assuming the heterozygote model. In the right plot, HWD-adjusted log ORs and 95%CI were used for the underlined studies (i.e., He, 2018; Kontorovich et al., 2010; Pratedrat et al., 2015; Jiang et al., 2016).

 Heterogeneity, Meta-regression, and Sensitivity Analysis

Heterogeneity was evaluated for both polymorphisms in all genetic models (Tables 3, 4, 5). Significant between study heterogeneity was observed in the overall estimation under all genetic models for mir-196a-2 rs11614913 and consequently random effect model was used. Univariate meta-regression using cancer type, country, ethnicity, the quality of study (either high or low), genotyping method, source of controls (PB or HB) or HWE was performed to identify potential sources of heterogeneity. For mir-196a-2, meta-regression showed that at least a part of the observed between study heterogeneity in the heterozygote (R2: 24.23%, P: 0.007) and dominant (R2: 19.86%, P: 0.028) models could be attributed to the country moderator. However, there was still significant unaccounted heterogeneity even after correcting for the effect of country moderator (Heterozygote I2: 63.78 and dominant I2: 72.05, P for test of residual heterogeneity < 0.0001). Moreover, Galbraith plot analysis demonstrated three studies (Lv et al., 2013; Wang et al., 2013; Dikeakos et al., 2014) as the most extreme outliers in all genetic models that account for a considerable portion of the observed heterogeneities (Supplementary Figure S7). Excluding these studies led to a 11.6% reduction of I2 in the homozygote model (from 77.1 to 65.5%), a 12.8% reduction in the heterozygote model (from 70.6 to 57.8%), a 12.3% reduction in the dominant model (from 76.9 to 64.6%), an 9.1% reduction in the recessive model (from 68.8 to 59.7%) and a 11.3% reduction in the allelic model (from 79 to 67.7%). However, excluding these studies did not alter any genotypic contrast and results were comparable to the overall analyses (data not shown). Sensitivity analysis by omitting one study at a time revealed that no individual study significantly influenced the genotype contrasts (Supplementary Figure S8). In the allele contrast, omitting no single study dramatically influenced pooled OR or its 95%CI. However, given that the original 95%CI was borderline (0.90–1.00), omitting some studies lead the upper limit of 95%CI to fall slightly below one (Supplementary Figure S8-e).

Statistically significant heterogeneity was also observed in the overall analysis of miR-149 rs2292832 and cancer risk and, consequently, RE model was used to estimate pooled OR (Table 3). Subgrouping by study level moderators led to a reduction in heterogeneity in some subgroups (Table 5). However, univariate meta-regression showed no statistically significant source of heterogeneity (All P > 0.05). Sensitivity analysis by omitting one study at a time revealed no single influential study (Supplementary Figure S9).

 Publication Bias

Rank correlation test of the mir-196a-2 rs11614913 Begger's funnel plot asymmetry revealed no statistically significant evidence of publication bias in any contrast (Table 3 and Supplementary Figure S10). However, rank correlation test for asymmetry of mir-149 rs2292832 funnel plots showed statistically significant results in the homozygote, recessive and the allelic contrasts (Table 3 and Supplementary Figure S11). Consequently, the “trim and fill” approach (Duval and Tweedie, 2000a,b) employed to correct for funnel plot asymmetry arising from publication bias in these models. The results of overall analysis using original studies or trim and fill method under the three models were comparable (see Supplementary Figure S4 to compare forest plots of the original studies vs. trim-and-fill method and Supplementary Figure S11 for funnel plots). After excluding studies with controls deviating from HWE in sensitivity analysis, rank correlation test was still significant in the mentioned three contrasts.

 Discussion

The possible contribution of miRNAs, especially mir-196a-2 and mir-149, to the risk of cancer has stimulated great attention in recent years. Many studies evaluated the functional alterations of these micro-regulators in a wide range of cancers. Accumulating evidence suggests that, at least a part of functional dysregulations of miRNAs in cancers could be attributed to polymorphisms in miRNA sequences (Hu et al., 2008; Hoffman et al., 2009; Tu et al., 2012; Ghaedi et al., 2015; Nariman-Saleh-Fam et al., 2016, 2017). Two mature miRNAs, miR-196a-5p and miR-196a-3p, are generated from the stem-loop structure of hsa-mir-196a-2 (Kozomara and Griffiths-Jones, 2014) with the studied polymorphism, rs11614913, residing in the 3′ arm (Figure 9A). This polymorphism, therefore, may potentially alter miRNA processing and also binding to related target mRNAs (Hoffman et al., 2009) (Figure 9B). Previous studies have shown that the expression level of mature miR-196a-3p was higher in CC carriers with lung cancer compared to CT and TT individuals (Hu et al., 2008). More evidences have been provided by Hoffman et al. (2009) who observed elevated expression of mature mir-196a-2 forms in MCF-7 cells transfected with pre-mir-196a-C vector compared with cells transfected with pre-mir-196a-T vector. The potential of rs11614913 in influencing targeting function of mir-196a-2 has also been documented by whole-genome expression microarrays which found different numbers of dysregulated mRNAs after transfecting cells with pre-mir-196a-C or pre-mir-196a-T vector (Hoffman et al., 2009). Hsa-mir-149 also generates two mature miRNAs (miR-149-5p and miR-149-3p) and the studied polymorphism, rs2292832, does not reside in the mature sequence of neither miR-149-5p or miR-149-3p (Figure 10A). Therefore, it has been hypothesized that rs2292832 is not a structure-shifting polymorphism for pri-mir-149 or pre-mir-149 (Wei et al., 2014). However, Tu et al. reported that the T allele may disrupt the maturation process compared with the C allele and, consequently, decrease miR-149 expression (Tu et al., 2012) (Figure 10B) in head and neck squamous cell carcinoma patients.

Schematic illustration of hsa-mir-196a-2 locus and effect of rs11614913 on its processing and targeting. (A) Top: Hsa-mir-196-a-2 generates two mature miRNAs, miR-196a-5p and mir-196a-3p, and rs11614913 lies in miR-196a-3p at GRCh37 chr12: 54,385,599. Bottom: Stem-loop structure of hsa-mir-196, including mature miR-196-5p (Red) and miR-196-3p (Blue) sequences. (B) Rs11614913 alters miRNA processing and/or binding to related target mRNAs.

Schematic illustration of hsa-mir-149 locus and effect of rs2292832 on its processing. (A) Top: Hsa-mir-149 generates two mature miRNAs (miR-149-5p and miR-149-3p), and rs2292832 resides in pre-miRNA sequence, but not in either mature miRNAs, at GRCh37 chr2: 241,395,593. Bottom: Stem-loop structure of hsa-mir-149, including mature miR-149-5p (Red), and miR-149-3p (Blue) sequences. (B) Rs12292832 may alter miRNA processing and decrease mature miR-149 (−5p and −3p forms) expression.

Increasing number of association studies evaluating miRNA polymorphisms and cancer risk with contradictory results merits the need for comprehensive systematic reviews and meta-analyses. Several meta-analyses have evaluated the risk of cancer associated with mir-196a-2 rs11614913 or mir-149 rs2292832 (Chu et al., 2011; Zhang H. et al., 2012; Feng et al., 2016; Yan et al., 2017; Liu et al., 2018). However, the conclusion of these studies with regards to the subgroup analysis and the significant genetic model varies due, at least in part, to differences in the number of studies included or in the methodology. Moreover, several recent genetic association studies have not been included in previously published meta-analyses. Therefore, it was necessary to perform an updated meta-analysis with larger number of studies to clarify the association of mir-196a-2 rs11614913 or mir-149 rs2292832 with cancer risk. Therefore, compared to the previous meta-analysis, we included more studies in the analyses. The present meta-analysis also evaluated and corrected for the possible influence of departure of the control group of association studies from HWE. Although checking for departure from HWE has been recommended, currently there is no consensus about how HWD studies should be handled in meta-analysis (Minelli et al., 2008). Result of simulations suggests no advantage for excluding these studies (Minelli et al., 2008). However, sensitivity analysis to detect any possible bias imposed by such studies and/or using HWE-expected counts instead of the observed genotype frequencies have been recommended and implemented in several studies (Attia et al., 2003; Thakkinstian et al., 2005; Trikalinos et al., 2006; Zintzaras et al., 2006; Zintzaras, 2008; Zintzaras and Lau, 2008; Srivastava and Srivastava, 2012; Wang X. B. et al., 2014). The current study noticed that most analyses, especially those with sufficiently large number of studies, were not influenced by excluding HWD studies. However, as it is rationally expected, excluding HWD studies from some subgroup with relatively small number of studies may influence the analysis, and therefore in such situations adjusted analyses were preferred.

For mir-196a-2 rs11614913, the previous largest meta-analysis, conducted by Liu et al. (2018), included 84 studies compared to 111 studies in the present meta-analysis. By including 41,673 patients and 49,570 control subjects, the present meta-analysis showed a decreased risk of cancer in the homozygote and the recessive models (Table 3). Although, the association was not significant in allele contrast, the OR and 95%CI of the allele contrast were borderline and influenced by excluding some individual studies. Excluding HWE-deviated or low quality studies yielded significant associations under allelic model. As there is, currently, no way to adjust allele frequencies for departure from HWE, the possibility that HWD studies may bias the allele contrast cannot be rolled out and a definite conclusion cannot be drawn under allelic model. Apart from the allele contrast, the results of other genetic models were statistically stable and not influenced by removing any single study, HWE deviated or low quality studies. The results also suggest that mir-196a-2 rs11614913 may pose an ethnic dependent effect on cancer risk as associations with cancer were only observed in Asians. However, it should be noted that most studies enrolled Asian patients, mainly Chinese patients, and the number of studies involving other ethnicities were relatively small. Moreover, different minor allele frequencies (MAF) may partly contribute to the observed differences among ethnicities (Average MAF in Asians T: 0.501 ± 0.127, Caucasians T: 0.410 ± 0.1, Others T: 0.338 ± 0.066). In-line with previous studies, the current meta-analysis also confirmed that rs11614913 is associated with decreased risks of hepatocellular cancer under three genetic models (Liu et al., 2018) and that it may not modulate risk of urogenital cancers (Wang et al., 2017). The results of meta-analysis of all studies, subgroup analysis by ethnicity and hepatocellular cancer are in agreement with findings of the previous largest meta-analysis (Liu et al., 2018). However, the increase in the number of analyzed studies led to discrepancies with regards to conclusions in some subgroup analysis. (i) In contrast to the studies by Liu and Pan (Pan et al., 2017; Liu et al., 2018), the present meta-analysis did not find a significant association with head and neck carcinoma in any genetic model. This discrepancy may be attributed to the number of studies included in meta-analyses [nine studies in the present meta-analysis compared to four studies in the meta-analysis by Liu et al. (2018)]. Furthermore, differences in defining head and neck cancer may also explain different conclusions drawn from the present study and the study by Pan and colleagues (Pan et al., 2017). They included esophageal cancer as a type of head and neck cancer, whereas we considered it as a type of gastrointestinal tract cancers (according to the ICD-10-CM C15-C26). (ii) Additionally, the present meta-analysis found significant associations between mir-196a-2 rs11614913 and decreased risks of gynecologic cancers (especially ovarian cancer), which have not been reported in any previous meta-analysis. Interestingly, low heterogeneity was observed in the gynecological cancers subgroup assuming the two significant contrasts (i.e., recessive and allelic). (iii) Although previous meta-analyses (Yan et al., 2017; Zhang H. et al., 2017; Liu et al., 2018) failed to find a significant association between mir-196a-2 rs11614913 and breast cancer, the current study showed, by incorporating more association studies and performing HWD sensitivity analysis, that adjusting for departure from HWE may reveal significant associations under the homozygote and recessive contrasts (Figure 6 and Supplementary Table S2). (iv) Moreover, contradictory to previous meta-analyses, no association with gastric (Yan et al., 2017), colorectal (Xie et al., 2015; Yan et al., 2017) or lung cancer (Ren et al., 2016; Yan et al., 2017; Liu et al., 2018), was found. Apart from larger sample sizes and correcting for HWD, sometimes this discrepancy in results may also be related to methodological differences in the design, specifically the inclusion criteria, of meta-analyses. As a case in point, studies by Hu et al. (2008) and Yoon et al. (2012) did not meet the inclusion criteria of our study, as they deal with the survival or recurrence risk of lung cancer patients with approaches that differed from routine case-control genetic association studies. However, we noticed that these studies were included in a previous meta-analysis (Liu et al., 2018).

The current meta-analysis also showed that mir-149 rs2292832 is not associated with risk of cancer in any genetic model and the results were statistically reliable, as summary effects were not influenced by excluding any single study, HWE-deviated or low quality studies. No differences in cancer risk was observed between ethnicities. Similar to miR-196a-2 polymorphism, the Asian subgroup comprised a large proportion of studies and relatively few studies with limited sample sizes were performed in Caucasians. Therefore, a definite conclusion cannot be drawn in Caucasians and more studies are needed further clarify the association of this SNP with cancer risk in Caucasians. The results of overall analysis were comparable to previous meta-analyses (Li L. et al., 2015; Feng et al., 2016). By pooling the results of 22 studies, this meta-analysis found a decreased risk of gastrointestinal tract (GI) cancers for individuals who carry the CT genotype compared to those with the CC genotype in a heterozygote model. Interestingly, there was no significant heterogeneity in the GI subgroup assuming the heterozygote model indicating the reliability of meta-analysis in this subgroup. Previous meta-analyses yielded different results with regard to GI cancers. A previous meta-analysis of seven studies on GI cancers suggested a marginally elevated risk under the recessive model (TT vs. CT+CC), while another pooling of 10 studies found a borderline decreased risk for the CT vs. TT contrast. Although no significant association was identified in the head and neck cancers subgroup, it should be noted that significant heterogeneity was present in all models except the recessive contrast and number of samples were relatively small. For colorectal cancer the association was in reverse direction and an increased risk was observed in individuals who carry the TT genotype compared with subject who carry at-least one C allele (Table 5). A similar association based on three studies was previously reported (Rong et al., 2017), but not reproduced in other meta-analyses (Li et al., 2013; Feng et al., 2016). Taken together, the current results based on five studies suggest an increased risk for colorectal cancer that was stable after correcting for departure from HWE. Although no significant heterogeneity was detected in the colorectal cancer subgroup under any genetic model, it should be noted that the limited number of studies may influence heterogeneity evaluation and more definite conclusion may be drawn by analyzing larger sample sizes. In the case of breast cancer, a previous meta-analysis of three studies found a significant association (Feng et al., 2016). We found no significant association in the original and HWD-adjusted analysis. However, number of studies in the colorectal and breast cancer subgroups are relatively limited and results should be interpreted with caution. More studies with large sample sizes are needed for a definite conclusion.

However, the present study has some limitations. First, significant heterogeneity was present in most analyses especially for mir-196a-2 polymorphism. We, therefore, used random effect model and performed meta-regression; but no significant source of heterogeneity was observed for most analyses, suggesting that other unknown study level moderators may contribute to the heterogeneity. Second: The molecular mechanisms underlying association of these miRNAs-SNP with risk of cancer are complex and might be strongly affected by different genetic background as well as other masked variables. This, in turn, may limit the efficacy of the overall analysis especially in the case of miR-196a-2 rs11614913. Stratified analyses based on a specific cancer category or a cancer type may help to reduce this heterogeneity and, therefore, are considered to be more reliable. Third, this study was based on unadjusted ORs of the original studies and no adjustment for covariates like age and gender or interaction with environmental factors were done and this fact may also potentially contribute to the between study heterogeneity. Fourth, some limitations such as language restriction or lack of access to the genotype counts of mir-196a-2 rs11614913 in four studies with insufficiently reported data may bring in publication bias. The trim and fill method has been shown to reduce the bias in estimates in the presence of publication bias and heterogeneity (Peters et al., 2007). However, it has been recommended that this method should be considered as sensitivity analysis as we cannot be sure that asymmetry in funnel plot is truly caused by publication bias (Peters et al., 2007). Although rank correlation test of funnel plots of mir-149 rs2292832 was significant in three genetic models raising the possibility of publication bias, adjusting for such a bias using trim-and-fill method did not afford any change in analysis of overall studies in these models (Supplementary Figure S4). Fifth, number of studies in some subgroup analyses was limited and, consequently, results of such analysis should be interpreted with caution. Most studies were performed enrolling Asian patients and the number of studies on Caucasians or Africans was limited. Therefore, more association studies with larger sample sizes on Africans and Caucasians are needed to make precise estimations of cancer risk associated with the studied polymorphisms. Assigning ethnicity to each study population could be another limitation of meta-analysis of association studies as each ethnicity may regroup several sub-populations with somewhat different genetic background. Sixth, the control groups of association studies were not uniformly defined and non-differential misclassification bias may have occurred.

In conclusion, this meta-analysis showed that mir-196a-2 rs11614913 T allele is associated with decreased cancer risk in overall population, high quality studies and studies on Asian populations. It is also associated with a decreased risk of gynecological cancers, ovarian, breast and hepatocellular cancer. Mir-149 rs2292832 was not associated with cancer risk in overall population, high quality studies, Asians or Caucasians. However, the T allele was associated with a decrease risk of gastrointestinal tract cancers under the heterozygote model and an increased risk of colorectal cancer under the recessive model.

 Author Contributions

MB and AM conceived the original idea and supervised the project. JC, ZN-S-F, and ZS contributed to the literature search and data management. MB, JC, and ZN-S-F wrote the manuscript with support from all authors. MB contributed to the data analysis, interpretation of results, and data visualization with inputs from AM. EO and ZS assisted with data visualization. All authors provided critical feedback, discussed the results, and contributed to the final manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

We would like to thank Dr. Karl Kelsey and Dr. Brock Christensen for providing the genotype counts of mir-196a-2 rs11614913 for their study (Christensen et al., 2010).

 Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2019.00186/full#supplementary-material

 References Abdel-Hamid M. Elshaer S. Darwish A. (2018). Association of MicroRNA related single nucleotide polymorphisms 196A-2 and 499 with the risk of hepatocellular carcinoma in Egyptian patients. Meta Gene. 16, 139–142. 10.1016/j.mgene.2018.02.007 Afsharzadeh S. M. Mohaddes Ardebili S. M. Seyedi S. M. Karimian Fathi N. Mojarrad M. (2017). Association between rs11614913, rs3746444, rs2910164 and occurrence of breast cancer in Iranian population. Meta Gene. 11, 20–25. 10.1016/j.mgene.2016.11.004 Ahn D. H. Rah H. Choi Y. K. Jeon Y. J. Min K. T. Kwack K. . (2013). Association of the miR-146aC>G, miR-149T>C, miR-196a2T>C, and miR-499A>G polymorphisms with gastric cancer risk and survival in the korean population. Mol. Carcinogene. 52, 39–51. 10.1002/mc.2196223001871 Akkiz H. Bayram S. Bekar A. Akgöllü E. Ülger Y. (2011). A functional polymorphism in pre-microRNA-196a-2 contributes to the susceptibility of hepatocellular carcinoma in a Turkish population: a case-control study. J Viral Hepatitis. 18, e399–e407. 10.1111/j.1365-2893.2010.01414.x21692953 Alshatwi A. A. Shafi G. Hasan T. N. Syed N. A. Al-Hazzani A. A. Alsaif M. A. . (2012). Differential expression profile and genetic variants of MicroRNAs sequences in breast cancer patients. PLoS ONE 7:030049. 10.1371/journal.pone.003004922363415 Attia J. Thakkinstian A. D'Este C. (2003). Meta-analyses of molecular association studies: methodologic lessons for genetic epidemiology. J. Clin. Epidemiol. 56, 297–303. 10.1016/S0895-4356(03)00011-812767405 Bansal C. Sharma K. L. Misra S. Srivastava A. N. Mittal B. Singh U. S. (2014). Common genetic variants in pre-microRNAs and risk of breast cancer in the North Indian population. Ecancermedicalscience 8:473. 10.3332/ecancer.2014.47325374621 Begg C. B. Mazumdar M. (1994). Operating characteristics of a rank correlation test for publication bias. Biometrics 50, 1088–1101. 10.2307/25334467786990 Bodal V. K. Sangwan S. Bal M. S. Kaur M. Sharma S. Kaur B. (2017). Association between microrna 146a and microrna 196a2 genes polymorphism and breast cancer risk in north indian women. Asian Pac. J. Cancer Prev. 18, 2345–2348. 10.22034/APJCP.2017.18.9.234528950676 Bray F. Jemal A. Grey N. Ferlay J. Forman D. (2012). Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 13, 790–801. 10.1016/S1470-2045(12)70211-522658655 Cîmpeanu R. A. Popescu D. M. Burada F. Cucu M. G. Gheonea D. I. Ioana M. . (2017). miR-149 rs2292832 C>T polymorphism and risk of gastric cancer. Roman. J. Morphol. Embryol. 58, 125–129. 28523307 Catucci I. Yang R. Verderio P. Pizzamiglio S. Heesen L. Hemminki K. . (2010). Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases. Hum. Mutat. 31, E1052–E1057. 10.1002/humu.2114119847796 Chen H. Sun L. Y. Chen L. L. Zheng H. Q. Zhang Q. F. (2012). A variant in microRNA-196a2 is not associated with susceptibility to and progression of colorectal cancer in Chinese. Inter. Med. J. 42, e115–e119. 10.1111/j.1445-5994.2011.02434.x21565628 Christensen B. C. Avissar-Whiting M. Ouellet L. G. Butler R. A. Nelson H. H. McClean M. D. . (2010). Mature microRNA sequence polymorphism in MIR196A2 is associated with risk and prognosis of head and neck cancer. Clin. Cancer Res. 16, 3713–3720. 10.1158/1078-0432.CCR-10-065720501619 Chu H. Wang M. Shi D. Ma L. Zhang Z. Tong N. . (2011). Hsa-miR-196a2 Rs11614913 polymorphism contributes to cancer susceptibility: evidence from 15 case-control studies. PLoS ONE 6:e18108. 10.1371/journal.pone.001810821483822 Chu Y. H. Hsieh M. J. Chiou H. L. Liou Y. S. Yang C. C. Yang S. F. . (2014). MicroRNA gene polymorphisms and environmental factors increase patient susceptibility to hepatocellular carcinoma. PLoS ONE 9:089930. 10.1371/journal.pone.008993024587132 Chu Y. H. Tzeng S. L. Lin C. W. Chien M. H. Chen M. K. Yang S. F. (2012). Impacts of microRNA gene polymorphisms on the susceptibility of environmental factors leading to carcinogenesis in oral cancer. PLoS ONE 7:39777. 10.1371/journal.pone.003977722761899 Dai Z. M. Kang H. F. Zhang W. G. Li H. B. Zhang S. Q. Ma X. B. . (2016). The associations of single nucleotide polymorphisms in miR196a2, miR-499, and miR-608 with breast cancer susceptibility: a STROBE-compliant observational study. Medicine 95:e2826. 10.1097/MD.000000000000282626886638 Damodaran M. Paul S. F. D. Venkatesan V. (2018). Genetic polymorphisms in miR-146a, miR-196a2 and miR-125a genes and its association in prostate cancer. Pathol. Oncol. Res. 1–8. 10.1007/s12253-018-0412-x29594807 [Epub ahead of print]. Deng S. Wang W. Li X. Zhang P. (2015). Common genetic polymorphisms in pre-microRNAs and risk of bladder cancer. World J. Surg. Oncol. 13:297. 10.1186/s12957-015-0683-626458899 DerSimonian R. Laird N. (1986). Meta-analysis in clinical trials. Control Clin. Trials 7, 177–188. 10.1016/0197-2456(86)90046-23802833 Dikaiakos P. Gazouli M. Rizos S. Zografos G. Theodoropoulos G. E. (2015). Evaluation of genetic variants in miRNAs in patients with colorectal cancer. Cancer Biomarkers 15, 163–168. 10.3233/CBM-14044925519012 Dikeakos P. Theodoropoulos G. Rizos S. Tzanakis N. Zografos G. Gazouli M. (2014). Association of the miR-146aC>G, miR-149T>C, and miR-196a2T>C polymorphisms with gastric cancer risk and survival in the Greek population. Mol. Biol. Rep. 41, 1075–1080. 10.1007/s11033-013-2953-024379078 Dong G. Zhang R. Xu J. Guo Y. (2015). Association between microRNA polymorphisms and papillary thyroid cancer susceptibility. Int. J. Clin. Exp. Pathol. 8, 13450–13457. 26722556 Dou T. Wu Q. Chen X. Ribas J. Ni X. Tang C. . (2010). A polymorphism of microRNA196a genome region was associated with decreased risk of glioma in Chinese population. J. Cancer Res. Clin. Oncol. 136, 1853–1859. 10.1007/s00432-010-0844-520229273 Doulah A. Salehzadeh A. Mojarrad M. (2018). Association of single nucleotide polymorphisms in miR-499 and miR-196a with susceptibility to breast cancer. Trop. J. Pharmaceut. Res. 17, 319–323. 10.4314/tjpr.v17i2.17 Du M. Lu D. Wang Q. Chu H. Tong N. Pan X. . (2014). Genetic variations in microRNAs and the risk and survival of renal cell cancer. Carcinogenesis 35, 1629–1635. 10.1093/carcin/bgu08224681820 Duval S. Tweedie R. (2000a). A Nonparametric “Trim and Fill” Method of Accounting for Publication Bias in Meta-Analysis. J. Am. Stat. Assoc. 95, 89–98. 10.2307/2669529 Duval S. Tweedie R. (2000b). Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56, 455–463. 10.1111/j.0006-341X.2000.00455.x10877304 Feng Y. Duan F. Song C. Zhao X. Dai L. Cui S. (2016). Systematic evaluation of cancer risk associated with rs2292832 in miR-149 and rs895819 in miR-27a: a comprehensive and updated meta-analysis. Oncotarget 7, 22368–22384. 10.18632/oncotarget.8082 Ferlay J. Shin H. R. Bray F. Forman D. Mathers C. Parkin D. M. (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int. J. Cancer 127, 2893–2917. 10.1002/ijc.2551621351269 George G. P. Gangwar R. Mandal R. K. Sankhwar S. N. Mittal R. D. (2011). Genetic variation in microRNA genes and prostate cancer risk in North Indian population. Mol. Biol. Rep. 38, 1609–1615. 10.1007/s11033-010-0270-420842445 Ghaedi H. Bastami M. Zare-Abdollahi D. Alipoor B. Movafagh A. Mirfakhraie R. . (2015). Bioinformatics prioritization of SNPs perturbing microRNA regulation of hematological malignancy-implicated genes. Genomics 106, 360–366. 10.1016/j.ygeno.2015.10.00426520014 Gu J. Y. Tu L. (2016). Investigating the role of polymorphisms in miR-146a,−149, and−196a2 in the development of gastric cancer. Genetics Mol. Res. 15:gmr.15027839. 10.4238/gmr.1502783927323019 Ha M. Kim V. N. (2014). Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15:509. 10.1038/nrm383825027649 Han Y. Pu R. Han X. Zhao J. Zhang Y. Zhang Q. . (2013). Associations of pri-miR-34b/c and pre-miR-196a2 polymorphisms and their multiplicative interactions with Hepatitis B virus mutations with hepatocellular carcinoma risk. PLoS ONE 8:058564. 10.1371/journal.pone.005856423516510 Hao Y. X. Wang J. P. Zhao L. F. (2014). Associations between three common MicroRNA polymorphisms and hepatocellular carcinoma risk in Chinese. Asian Pac. J. Cancer Prevent. 14, 6601–6604. 10.7314/APJCP.2013.14.11.660124377574 Hashemi M. Moradi N. Ziaee S. A. Narouie B. Soltani M. H. Rezaei M. . (2016). Association between single nucleotide polymorphism in miR-499, miR-196a2, miR-146a and miR-149 and prostate cancer risk in a sample of Iranian population. J. Adv. Res. 7, 491–498. 10.1016/j.jare.2016.03.00827222754 He B. Pan Y. Xu Y. Deng Q. Sun H. Gao T. . (2015). Associations of polymorphisms in microRNAs with female breast cancer risk in Chinese population. Tumor Biol. 36, 4575–4582. 10.1007/s13277-015-3102-225613069 He J. Zou Y. Liu X. Zhu J. Zhang J. Zhang R. . (2018). Association of common genetic variants in pre-microRNAs and neuroblastoma susceptibility: a two-center study in chinese children. Mol. Ther. Nucleic Acids 11, 1–8. 10.1016/j.omtn.2018.01.00329858046 He Y. Yu D. Zhu L. Zhong S. Zhao J. Tang J. (2018). miR-149 in human cancer: a systemic review. J. Cancer 9, 375–388. 10.7150/jca.2104429344284 Hezova R. Kovarikova A. Bienertova-Vasku J. Sachlova M. Redova M. Vasku A. . (2012). Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J. Gastroenterol. 18, 2827–2831. 10.3748/wjg.v18.i22.282722719192 Hoffman A. E. Zheng T. Yi C. Leaderer D. Weidhaas J. Slack F. . (2009). microRNA miR-196a-2 and breast cancer: a genetic and epigenetic association study and functional analysis. Cancer Res. 69, 5970–5977. 10.1158/0008-5472.CAN-09-023619567675 Hong Y. S. Kang H. J. Kwak J. Y. Park B. L. You C. H. Kim Y. M. . (2011). Association between MicroRNA196a2 rs11614913 genotypes and the risk of non-small cell lung cancer in Korean population. J. Prevent. Med. Public Health 44, 125–130. 10.3961/jpmph.2011.44.3.12521617338 Horikawa Y. Wood C. G. Yang H. Zhao H. Ye Y. Gu J. . (2008). Single nucleotide polymorphisms of microRNA machinery genes modify the risk of renal cell carcinoma. Clin. Cancer Res. 14, 7956–7962. 10.1158/1078-0432.CCR-08-119919047128 Hu E. Wang D. Zhang X. Li J. Hu Y. Gong H. . (2013). Four common polymorphisms in microRNAs and the risk of adult glioma in a Chinese case-control study. J. Mol. Neurosci. 51, 933–940. 10.1007/s12031-013-9980-023430406 Hu Z. Chen J. Tian T. Zhou X. Gu H. Xu L. . (2008). Genetic variants of miRNA sequences and non–small cell lung cancer survival. J. Clin. Invest. 118, 2600–2608. 10.1172/JCI3493418521189 Hu Z. Liang J. Wang Z. Tian T. Zhou X. Chen J. . (2009). Common genetic variants in pre-microRNAs were associated with increased risk of breast cancer in Chinese women. Hum. Mutat. 30, 79–84. 10.1002/humu.2083718634034 Huang G. L. Lu Y. Pu X. X. He Y. X. Chen M. L. Li Y. Z. . (2013). Association study between miR-149 gene polymorphism and nasopharyngeal carcinoma. Biomed. Rep. 1, 599–603. 10.3892/br.2013.9724648993 Huang Y. Sheng S. Chen B. Lin R. Yang J. Hao B. (2017). MiR-146a genetic polymorphism contributes to the susceptibility to hepatocellular carcinoma in a Chinese population. Int. J. Clin. Exp. Pathol. 10, 1833–1839. Jedlinski D. J. Gabrovska P. N. Weinstein S. R. Smith R. A. Griffiths L. R. (2011). Single nucleotide polymorphism in hsa-mir-196a-2 and breast cancer risk: a case control study. Twin Res. Hum. Genetics 14, 417–421. 10.1375/twin.14.5.41721962133 Jiang J. Jia Z. F. Cao D. H. Wu Y. H. Sun Z. W. Cao X. Y. (2016). Association of the MIR-146a rs2910164 polymorphism with gastric cancer susceptibility and prognosis. Future Oncol. 12, 2215–2226. 10.2217/fon-2016-022427267319 Kim M. J. Yoo S. S. Choi Y. Y. Park J. Y. (2010). A functional polymorphism in the pre-microRNA-196a2 and the risk of lung cancer in a Korean population. Lung Cancer 69, 127–129. 10.1016/j.lungcan.2010.04.01520466450 Kim W. H. Min K. T. Jeon Y. J. Kwon C.-I. Ko K. H. Park P. W. . (2012). Association study of microRNA polymorphisms with hepatocellular carcinoma in Korean population. Gene 504, 92–97. 10.1016/j.gene.2012.05.01422583825 Kontorovich T. Levy A. Korostishevsky M. Nir U. Friedman E. (2010). Single nucleotide polymorphisms in miRNA binding sites and miRNA genes as breast/ovarian cancer risk modifiers in Jewish high-risk women. Int. J. Cancer 127, 589–597. 10.1002/ijc.2506519950226 Kou J. T. Fan H. Han D. Li L. Li P. Zhu J. . (2014). Association between four common microRNA polymorphisms and the risk of hepatocellular carcinoma and HBV infection. Oncol. Lett. 8, 1255–1260. 10.3892/ol.2014.225725120701 Kozomara A. Griffiths-Jones S. (2014). miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 42, D68–D73. 10.1093/nar/gkt118124275495 Kupcinskas J. Bruzaite I. Juzenas S. Gyvyte U. Jonaitis L. Kiudelis G. . (2014a). Lack of association between miR-27a, miR-146a, miR-196a-2, miR-492 and miR-608 gene polymorphisms and colorectal cancer. Sci. Rep. 4:5993. 10.1038/srep0599325103961 Kupcinskas J. Wex T. Link A. Leja M. Bruzaite I. Steponaitiene R. . (2014b). Gene polymorphisms of micrornas in helicobacter pylori-induced high risk atrophic gastritis and gastric cancer. PLoS ONE 9:087467. 10.1371/journal.pone.008746724475294 Lau J. Ioannidis J. P. Schmid C. H. (1997). Quantitative synthesis in systematic reviews. Ann. Intern. Med. 127, 820–826. 10.7326/0003-4819-127-9-199711010-000089382404 Li H. Ren Y. Xia L. Qu R. Kong L. Yin Z. . (2016). Association of microrna-149 polymorphism with lung cancer risk in Chinese non-smoking female: a case-control study. PLoS ONE 11:163626. 10.1371/journal.pone.016362627685326 Li J. Cheng G. Wang S. (2016). A single-nucleotide polymorphism of miR-196a2T&gt;C rs11614913 is associated with hepatocellular carcinoma in the chinese population. Genetic Test. Mol. Biomarkers 20, 213–215. 10.1089/gtmb.2015.027126866381 Li L. Liu T. Li Z. Zhang L. Zhang Z. (2015). The miR-149 rs2292832 T/C polymorphism may decrease digestive cancer susceptibility: an updated meta-analysis. Int. J. Clin. Exp. Med. 8, 15351–15361. 26629024 Li L. Sheng Y. Lv L. Gao J. (2013). The association between two MicroRNA variants (miR-499, miR-149) and gastrointestinal cancer risk: a meta-analysis. PLOS ONE 8:e81967. 10.1371/journal.pone.008196724312386 Li M. Li R. J. Bai H. Xiao P. Liu G. J. Guo Y. W. . (2016). Association between the pre-miR-196a2 rs11614913 polymorphism and gastric cancer susceptibility in a Chinese population. Genetics Mol. Res. 15:gmr.15027516. 10.4238/gmr.1502751627173281 Li M. Marin-Muller C. Bharadwaj U. Chow K.-H. Yao Q. Chen C. (2009). MicroRNAs: control and loss of control in human physiology and disease. World J. Surg. 33, 667–684. 10.1007/s00268-008-9836-x19030926 Li P. Yan H. Zhang H. Yu L. Wang Z. Zhai Y. . (2014). A functional polymorphism in MIR196A2 is associated with risk and progression of nasopharyngeal carcinoma in the Chinese population. Genetic Test. Mol. Biomarkers 18, 149–155. 10.1089/gtmb.2013.040024328526 Li T. Niu L. Wu L. Gao X. Li M. Liu W. . (2015). A functional polymorphism in microRNA-196a2 is associated with increased susceptibility to non-Hodgkin lymphoma. Tumor Biol. 36, 3279–3284. 10.1007/s13277-014-2957-y25501512 Li X. Li K. Wu Z. (2015). Association of four common SNPs in microRNA polymorphisms with the risk of hepatocellular carcinoma. Int. J. Clin. Exp. Pathol. 8, 9560–9566. 26464719 Li X.-D. Li Z.-G. Song X.-X. Liu C.-F. (2010). A variant in microRNA-196a2 is associated with susceptibility to hepatocellular carcinoma in Chinese patients with cirrhosis. Pathology 42, 669–673. 10.3109/00313025.2010.52217521080878 Liberati A. Altman D. G. Tetzlaff J. Mulrow C. Gøtzsche P. C. Ioannidis J. P. A. . (2009). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700. 10.1136/bmj.b270019622552 Linhares J. J. Azevedo M. Jr Siufi A. A. de Carvalho C. V. Wolgien M. D. C. G. M. Noronha E. C. . (2012). Evaluation of single nucleotide polymorphisms in microRNAs (hsa-miR-196a2 rs11614913 C/T) from Brazilian women with breast cancer. BMC Med. Genetics 13:119. 10.1186/1471-2350-13-11923228090 Liu C. J. Tsai M. M. Tu H. F. Lui M. T. Cheng H. W. Lin S. C. (2013). MiR-196a overexpression and mir-196a2 gene polymorphism are prognostic predictors of oral carcinomas. Ann. Surg. Oncol. 20, S406–S414. 10.1245/s10434-012-2618-623138850 Liu M. F. Chen W. Q. He Y. Z. Gu Y. L. (2014). Role of miR-149C>T polymorphisms on the risk of hepatocellular carcinoma in aChinese population. Genetics Mol. Res. 13, 7184–7189. 10.4238/2014.September.5.425222224 Liu X. Y. (2015). Association of SNPS in miR-146a, miR-196a2 and miR-499 with risk of endometrial/ovarian cancer. Clin. Chem. Lab. Med. 53:S400. 10.1093/abbs/gmv042 Liu Y. He A. Liu B. Zhong Y. Liao X. Yang J. . (2018). rs11614913 polymorphism in miRNA-196a2 and cancer risk: an updated meta-analysis. OncoTargets Ther. 11, 1121–1139. 10.2147/OTT.S15421129535537 Liu Z. Li G. Wei S. Niu J. El-Naggar A. K. Sturgis E. M. . (2010). Genetic variants in selected pre-microrna genes and the risk of squamous cell carcinoma of the head and neck. Cancer 116, 4753–4760. 10.1002/cncr.2532320549817 Lu Y.-C. Chang J. T. Chan E.-C. Chao Y.-K. Yeh T.-S. Chen J.-S. . (2016). miR-196, an emerging cancer biomarker for digestive tract cancers. J. Cancer 7, 650–655. 10.7150/jca.1346027076845 Lv M. Dong W. Li L. Zhang L. Su X. Wang L. . (2013). Association between genetic variants in pre-miRNA and colorectal cancer risk in a Chinese population. J. Cancer Res. Clin. Oncol. 139, 1405–1410. 10.1007/s00432-013-1456-723728616 Ma F. Zhang P. Lin D. Yu D. Yuan P. Wang J. . (2013). There is no association between microRNA gene polymorphisms and risk of triple negative breast cancer in a Chinese Han population. PLoS ONE 8:e60195. 10.1371/journal.pone.006019523555923 Mantel N. Haenszel W. (1959). Statistical aspects of the analysis of data from retrospective studies of disease. J. Natl. Cancer Inst. 22, 719–748. 13655060 Martin-Guerrero I. Gutierrez-Camino A. Lopez-Lopez E. Bilbao-Aldaiturriaga N. Pombar-Gomez M. Ardanaz M. . (2015). Genetic variants in MiRNA processing genes and Pre-MiRNAs are associated with the risk of chronic lymphocytic leukemia. PLoS ONE 10:0118905. 10.1371/journal.pone.011890525793711 Mashayekhi S. Saeidi Saedi H. Salehi Z. Soltanipour S. Mirzajani E. (2018). Effects of miR-27a, miR-196a2 and miR-146a polymorphisms on the risk of breast cancer. Br. J. Biomed. Sci. 75, 76–81. 10.1080/09674845.2017.139957229521182 Miao L. Wang L. Zhu L. Du J. Zhu X. Niu Y. . (2016). Association of microRNA polymorphisms with the risk of head and neck squamous cell carcinoma in a Chinese population: a case-control study. Chin. J. Cancer 35:77. 10.1186/s40880-016-0136-927515039 Min K. T. Kim J. W. Jeon Y. J. Jang M. J. Chong S. Y. Oh D. . (2012). Association of the miR-146aC>G, 149C>T, 196a2C>T, and 499A>G polymorphisms with colorectal cancer in the Korean population. Mol. Carcinogenesis 51, E65–E73. 10.1002/mc.2184922161766 Minelli C. Thompson J. R. Abrams K. R. Thakkinstian A. Attia J. (2008). How should we use information about HWE in the meta-analyses of genetic association studies? Int. J. Epidemiol. 37, 136–146. 10.1093/ije/dym23418037675 Minh T. T. H. Thanh N. T. N. Van Thiep T. Hue N. T. (2018). Association between single nucleotide polymorphism Rs11614913 (C>T) on Mir-196a2 and breast cancer in vietnamese population, in 6th International Conference on the Development of Biomedical Engineering in Vietnam (BME6), Vol. 63, eds T. Vo Van, T. Nguyen Le, and T. Nguyen Duc, BME 2017. IFMBE Proceedings (Singapore: Springer). Mittal R. D. Gangwar R. George G. P. Mittal T. Kapoor R. (2011). Investigative role of Pre-MicroRNAs in bladder cancer patients: a case-control study in North India. DNA Cell Biol. 30, 401–406. 10.1089/dna.2010.115921345130 Morales S. Gulppi F. Gonzalez-Hormazabal P. Fernandez-Ramires R. Bravo T. Reyes J. M. . (2016). Association of single nucleotide polymorphisms in Pre-miR-27a, Pre-miR-196a2, Pre-miR-423, miR-608 and Pre-miR-618 with breast cancer susceptibility in a South American population. BMC Genetics 17:109. 10.1186/s12863-016-0415-027421647 Nariman-Saleh-Fam Z. Bastami M. Somi M. H. Behjati F. Mansoori Y. Daraei A. . (2017). miRNA-related polymorphisms in miR-423 (rs6505162) and PEX6 (rs1129186) and risk of esophageal squamous cell carcinoma in an iranian cohort. Genet. Test. Mol. Biomarkers 21, 382–390. 10.1089/gtmb.2016.034628430524 Nariman-Saleh-Fam Z. Bastami M. Somi M. H. Samadi N. Abbaszadegan M. R. Behjati F. . (2016). In silico dissection of miRNA targetome polymorphisms and their role in regulating miRNA-mediated gene expression in esophageal cancer. Cell Biochem. Biophys. 74, 483–497. 10.1007/s12013-016-0754-527518186 Ni J. Huang Y. (2016). Role of polymorphisms in miR-146a, miR-149, miR-196a2 and miR-499 in the development of ovarian cancer in a Chinese population. Int. J. Clin. Exp. Pathol. 9, 5706–5711. Nikolić Z. Savić Pavićević D. Vucić N. Cidilko S. Filipovic N. Cerovic S. . (2015). Assessment of association between genetic variants in microRNA genes hsa-miR-499, hsa-miR-196a2 and hsa-miR-27a and prostate cancer risk in Serbian population. Exp. Mol. Pathol. 99, 145–150. 10.1016/j.yexmp.2015.06.00926112096 Okubo M. Tahara T. Shibata T. Yamashita H. Nakamura M. Yoshioka D. . (2010). Association between common genetic variants in Pre-microRNAs and gastric cancer risk in japanese population. Helicobacter 15, 524–531. 10.1111/j.1523-5378.2010.00806.x21073609 Omrani M. Hashemi M. Eskandari-Nasab E. Hasani S. S. Mashhadi M. A. Arbabi F. . (2014). Hsa-mir-499 rs3746444 gene polymorphism is associated with susceptibility to breast cancer in an Iranian population. Biomarkers Med. 8, 259–267. 10.2217/bmm.13.11824521023 Osada H. Takahashi T. (2007). MicroRNAs in biological processes and carcinogenesis. Carcinogenesis 28, 2–12. 10.1093/carcin/bgl18517028302 Ow S. H. Chua P. J. Bay B. H. (2018). miR-149 as a Potential Molecular Target for Cancer. Curr. Med. Chem. 25, 1046–1054. 10.2174/092986732466617071810273828721828 Pan W. Wu C. Su Z. Duan Z. Li L. Mi F. . (2017). Genetic polymorphisms of non-coding RNAs associated with increased head and neck cancer susceptibility: a systematic review and meta-analysis. Oncotarget 8, 62508–62523. 10.18632/oncotarget.2009628977965 Parlayan C. Ikeda S. Sato N. Sawabe M. Muramatsu M. Arai T. (2014). Association analysis of single nucleotide polymorphisms in miR-146a and miR-196a2 on the prevalence of cancer in elderly Japanese: a case-control study. Asian Pac. J. Cancer Prevent. 15, 2101–2107. 10.7314/APJCP.2014.15.5.210124716941 Pavlakis E. Papaconstantinou I. Gazouli M. Theodosopoulos T. Karamanolis G. Genatas K. . (2013). MicroRNA gene polymorphisms in pancreatic cancer. Pancreatology 13, 273–278. 10.1016/j.pan.2013.02.00523719600 Peckham-Gregory E. C. Thapa D. R. Martinson J. Duggal P. Penugonda S. Bream J. H. . (2016). MicroRNA-related polymorphisms and non-Hodgkin lymphoma susceptibility in the Multicenter AIDS Cohort Study. Cancer Epidemiol. 45, 47–57. 10.1016/j.canep.2016.09.00727701053 Peng S. Kuang Z. Sheng C. Zhang Y. Xu H. Cheng Q. (2010). Association of MicroRNA-196a-2 gene polymorphism with gastric cancer risk in a Chinese population. Digest. Dis. Sci. 55, 2288–2293. 10.1007/s10620-009-1007-x19834808 Peng Y. Croce C. M. (2016). The role of MicroRNAs in human cancer. Signal Transduct. Targeted Ther. 1:15004. 10.1038/sigtrans.2015.429263891 Peters J. L. Sutton A. J. Jones D. R. Abrams K. R. Rushton L. (2007). Performance of the trim and fill method in the presence of publication bias and between-study heterogeneity. Stat. Med. 26, 4544–4562. 10.1002/sim.288917476644 Poltronieri-Oliveira A. B. Madeira F. F. Nunes D. B. S. M. Rodrigues G. H. Lopes B. C. Manoel-Caetano F. S. . (2017). Polymorphisms of miR-196a2 (rs11614913) and miR-605 (rs2043556) confer susceptibility to gastric cancer. Gene Rep. 7, 154–163. 10.1016/j.genrep.2017.04.006 Pratedrat P. Sopipong W. Makkoch J. Praianantathavorn K. Chuaypen N. Tangkijvanich P. . (2015). Single nucleotide polymorphisms in miR-149 (rs2292832) and miR-101-1 (rs7536540) are not associated with hepatocellular carcinoma in thai patients with Hepatitis B virus infection. Asian Pac. J. Cancer Prevent. 16, 6457–6461. 10.7314/APJCP.2015.16.15.6457 Pu J. Y. Dong W. Zhang L. Liang W. B. Yang Y. Lv M. L. (2014). No association between single nucleotide polymorphisms in pre-mirnas and the risk of gastric cancer in Chinese population. Iran. J. Basic Med. Sci. 17, 128–133. 10.22038/IJBMS.2014.224624711897 Qi J. H. Wang J. Chen J. Shen F. Huang J. T. Sen S. . (2014). High-resolution melting analysis reveals genetic polymorphisms in MicroRNAs confer hepatocellular carcinoma risk in Chinese patients. BMC Cancer 14:643. 10.1186/1471-2407-14-64325176041 Qi P. Dou T.-h. Geng L. Zhou F.-g. Gu X. Wang H. . (2010). Association of a variant in MIR 196A2 with susceptibility to hepatocellular carcinoma in male Chinese patients with chronic hepatitis B virus infection. Hum. Immunol. 71, 621–626. 10.1016/j.humimm.2010.02.01720188135 Qi P. Wang L. Zhou B. Yao W. J. Xu S. Zhou Y. . (2015). Associations of miRNA polymorphisms and expression levels with breast cancer risk in the Chinese population. Genet. Mol. Res. 14, 6289–6296. 10.4238/2015.June.11.226125831 Qu Y. Qu H. Luo M. Wang P. Song C. Wang K. . (2014). MicroRNAs related polymorphisms and genetic susceptibility to esophageal squamous cell carcinoma. Mol. Genet. Genom. 289, 1123–1130. 10.1007/s00438-014-0873-x24916311 Rakmanee S. Pakakasama S. Hongeng S. Sanguansin S. Thongmee A. Pongstaporn W. (2017). Increased risk of Thai childhood acute lymphoblastic leukemia with the MiR196a2 T &gt; C polymorphism. Asian Pac. J. Cancer Prevent. 18, 1117–1120. 10.22034/APJCP.2017.18.4.111728547950 Ranjbar R. Chaleshi V. Aghdaei H. A. Morovvati S. (2018). Investigating the association between miR-608 rs4919510 and miR-149 rs2292832 with Colorectal Cancer in Iranian Population. Microrna 7, 100–106 10.2174/221153660766618020614554029412127 Ren Y.-G. Zhou X.-M. Cui Z.-G. Hou G. (2016). Effects of common polymorphisms in miR-146a and miR-196a2 on lung cancer susceptibility: a meta-analysis. J. Thoracic Dis. 8, 1297–1305. 10.21037/jtd.2016.05.0227293850 Rogoveanu I. Burada F. Cucu M. G. Vere C. C. Ioana M. Cîmpeanu R. A. (2017). Association of microRNA polymorphisms with the risk of gastric cancer in a Romanian population. J. Gastrointest. Liver Dis. 26, 231–238. 10.15403/jgld.2014.1121.263.rog28922434 Rong G.-Q. Zhang X.-M. Chen B. Yang X.-D. Wu H.-R. Gong W. (2017). MicroRNA gene polymorphisms and the risk of colorectal cancer. Oncol. Lett. 13, 3617–3623. 10.3892/ol.2017.588528521462 Roy R. De Sarkar N. Ghose S. Paul R. R. Pal M. Bhattacharya C. . (2014). Genetic variations at microRNA and processing genes and risk of oral cancer. Tumour Biol. 35, 3409–3414. 10.1007/s13277-013-1450-324297336 Schwarzer G. (2007). meta: An R package for meta-analysis. R. News 3, 40–45. Shen F. Chen J. Guo S. Zhou Y. Zheng Y. Yang Y. . (2016). Genetic variants in miR-196a2 and miR-499 are associated with susceptibility to esophageal squamous cell carcinoma in Chinese Han population. Tumor Biol. 37, 4777–4784. 10.1007/s13277-015-4268-326518769 Sodhi K. K. Bahl C. Singh N. Behera D. Sharma S. (2015). Functional genetic variants in pre-MIR-146a and 196a2 genes are associated with risk of lung cancer in North Indians. Future Oncol. 11, 2159–2173. 10.2217/fon.15.14326235181 Song Z. S. Wu Y. Zhao H. G. Liu C. X. Cai H. Y. Guo B. Z. . (2016). Association between the rs11614913 variant of miRNA-196a-2 and the risk of epithelial ovarian cancer. Oncol. Lett. 11, 194–200. 10.3892/ol.2015.387726870188 Srivastava K. Srivastava A. (2012). Comprehensive review of genetic association studies and meta-analyses on miRNA polymorphisms and cancer risk. PLoS ONE 7:e50966. 10.1371/journal.pone.005096623226435 Srivastava K. Srivastava A. Mittal B. (2010). Common genetic variants in pre-microRNAs and risk of gallbladder cancer in North Indian population. J. Hum. Genet. 55, 495–499. 10.1038/jhg.2010.5420520619 Srivastava S. Singh S. Fatima N. Mittal B. Srivastava A. N. (2017). Pre-microrna gene polymorphisms and risk of cervical squamous cell carcinoma. J. Clin. Diagnostic Res. 11, GC01–GC04. 10.7860/JCDR/2017/25361.1054329207732 Su R. Li W. Luo R. (2016). Association between miR-146a, miR-149, miR-196a2 and miR-499 gene polymorphisms and the susceptibility to gastric cancer in a Chinese population. Int. J. Clin. Exp. Pathol. 9, 2192–2199. Sun X. C. Zhang A. C. Tong L. L. Wang K. Wang X. Sun Z. Q. . (2016). miR-146a and miR-196a2 polymorphisms in ovarian cancer risk. Genet. Mol. Res. 15:gmr.15038468. 10.4238/gmr.1503846827706635 Sushma P. S. Jamil K. Uday Kumar P. Satyanarayana U. Ramakrishna M. Triveni B. (2015). Genetic variation in microRNAs and risk of oral squamous cell carcinoma in South Indian population. Asian Pac. J. Cancer Prevent. 16, 7589–7594. 10.7314/APJCP.2015.16.17.758926625766 Tandon D. Dewangan J. Srivastava S. Garg V. K. Rath S. K. (2017). MiRNA genetic variants: as potential diagnostic biomarkers for oral cancer. Pathol. Res. Pract. 214, 281–289. 10.1016/j.prp.2017.10.00229103762 Thakkinstian A. McElduff P. D'Este C. Duffy D. Attia J. (2005). A method for meta-analysis of molecular association studies. Stat. Med. 24, 1291–1306. 10.1002/sim.201015568190 Thakkinstian A. McKay G. J. McEvoy M. Chakravarthy U. Chakrabarti S. Silvestri G. . (2011). Systematic review and meta-analysis of the association between complement component 3 and age-related macular degeneration: a HuGE review and meta-analysis. Am. J. Epidemiol. 173, 1365–1379. 10.1093/aje/kwr02521576320 Tian T. Shu Y. Chen J. Hu Z. Xu L. Jin G. . (2009). A functional genetic variant in microRNA-196a2 is associated with increased susceptibility of lung cancer in Chinese. Cancer Epidemiol. Biomarkers Prevent. 18, 1183–1187. 10.1158/1055-9965.EPI-08-081419293314 Tong N. Xu B. Shi D. Du M. Li X. Sheng X. . (2014). Hsa-miR-196a2 polymorphism increases the risk of acute lymphoblastic leukemia in Chinese children. Mutat. Res. 759, 16–21. 10.1016/j.mrfmmm.2013.11.00424291415 Toraih E. A. Fawz M. S. Elgazzaz M. G. Hussein M. H. Shehata R. H. Daoud H. G. (2016a). Combined genotype analyses of precursor miRNA196a2 and 499a variants with hepatic and renal cancer susceptibility a preliminary study. Asian Pac. J. Cancer Prevent. 17, 3369–3375. 27509977 Toraih E. A. Fawzy M. S. Mohammed E. A. Hussein M. H. EL-Labban M. M. (2016b). MicroRNA-196a2 biomarker and targetome network analysis in solid tumors. Mol. Diagn. Ther. 20, 559–577. 10.1007/s40291-016-0223-227342110 Trikalinos T. A. Salanti G. Khoury M. J. Ioannidis J. P. (2006). Impact of violations and deviations in Hardy-Weinberg equilibrium on postulated gene-disease associations. Am. J. Epidemiol. 163, 300–309. 10.1093/aje/kwj04616410351 Tu H. F. Liu C. J. Chang C. L. Wang P. W. Kao S. Y. Yang C. C. . (2012). The association between genetic polymorphism and the processing efficiency of miR-149 affects the prognosis of patients with head and neck squamous cell carcinoma. PLoS ONE 7:051606. 10.1371/journal.pone.005160623272122 Umar M. Upadhyay R. Prakash G. Kumar S. Ghoshal U. C. Mittal B. (2013). Evaluation of common genetic variants in pre-microRNA in susceptibility and prognosis of esophageal cancer. Mol. Carcinogenesis 52, 10–18. 10.1002/mc.2193122692992 Vinci S. Gelmini S. Mancini I. Malentacchi F. Pazzagli M. Beltrami C. . (2013). Genetic and epigenetic factors in regulation of microRNA in colorectal cancers. Methods 59, 138–146. 10.1016/j.ymeth.2012.09.00222989523 Vinci S. Gelmini S. Pratesi N. Conti S. Malentacchi F. Simi L. . (2011). Genetic variants in miR-146a, miR-149, miR-196a2, miR-499 and their influence on relative expression in lung cancers. Clin. Chem. Lab. Med. 49, 2073–2080. 10.1515/CCLM.2011.70821902575 Wang J. Zhang Y. Zhang Y. Chen L. (2016). Correlation between miRNA-196a2 and miRNA-499 polymorphisms and bladder cancer. Int. J. Clin. Exp. Med. 9, 20484–20488. Wang K. Guo H. Hu H. Xiong G. Guan X. Li J. . (2010). A functional variation in pre-microRNA-196a is associated with susceptibility of esophageal squamous cell carcinoma risk in Chinese Han. Biomarkers 15, 614–618. 10.3109/1354750X.2010.50529920722507 Wang N. Li Y. Zhou R. M. Wang G. Y. Wang C. M. Chen Z. F. . (2014). Hsa-miR-196a2 functional SNP is associated with the risk of ESCC in individuals under 60 years old. Biomarkers 19, 43–48. 10.3109/1354750X.2013.86616424320161 Wang R. Zhang J. Ma Y. Chen L. Guo S. Zhang X. . (2014). Association study of miR149 rs2292832 and miR608 rs4919510 and the risk of hepatocellular carcinoma in a largescale population. Mol. Med. Rep. 10, 2736–2744. 10.3892/mmr.2014.253625190221 Wang S. Tao G. Wu D. Zhu H. Gao Y. Tan Y. . (2013). A functional polymorphism in MIR196A2 is associated with risk and prognosis of gastric cancer. Mol. Carcinogenesis 52, 87–95. 10.1002/mc.2201723423813 Wang X. B. Cui N. H. Yang J. Qiu X. P. Gao J. J. Yang N. . (2014). Angiotensin-converting enzyme insertion/deletion polymorphism is not a major determining factor in the development of sporadic alzheimer disease: evidence from an updated meta-analysis. PLoS ONE 9:e111406. 10.1371/journal.pone.0111406 Wang X. H. Wang F. R. Tang Y. F. Zou H. Z. Zhao Y. Q. (2014). Association of miR-149C>T and miR-499A>G polymorphisms with the risk of hepatocellular carcinoma in the Chinese population. Genetics Mol. Res. 13, 5048–5054. 10.4238/2014.July.4.2025061729 Wang Y.-H. Hu H.-N. Weng H. Chen H. Luo C.-L. Ji J. . (2017). Association between polymorphisms in MicroRNAs and risk of urological cancer: a meta-analysis based on 17,019 subjects. Front. Physiol. 8:325. 10.3389/fphys.2017.0097528579964 Wei J. Zheng L. Liu S. Yin J. Wang L. Wang X. . (2013). MiR-196a2 rs11614913 T &gt; C polymorphism and risk of esophageal cancer in a Chinese population. Hum. Immunol. 74, 1199–1205. 10.1016/j.humimm.2013.06.01223792053 Wei W. J. Lu Z. W. Li D. S. Wang Y. Zhu Y. X. Wang Z. Y. . (2014). Association of the miR-149 Rs2292832 polymorphismwith papillary thyroid cancer risk and clinicopathologic characteristics in a Chinese population. Int. J. Mol. Sci. 15, 20968–20981. 10.3390/ijms15112096825405731 Xie M. Li Y. Wu J. Wu J. (2015). A risk of digestive tract neoplasms susceptibility in miR-146a and miR-196a2. Famil. Cancer 14, 229–239. 10.1007/s10689-014-9776-625555557 Xue W. Zhu M. Wang Y. He J. Zheng L. (2015). Association between PLCE1 rs2274223 A > G polymorphism and cancer risk: proof from a meta-analysis. Sci. Rep. 5:7986. 10.1038/srep0798625614244 Yan P. Xia M. Gao F. Tang G. Zeng H. Yang S. . (2015). Predictive role of miR-146a rs2910164 (C>G), miR-149 rs2292832 (T>C), miR-196a2 rs11614913 (T>C) and miR-499 rs3746444 (T>C) in the development of hepatocellular carcinoma. Int. J. Clin. Exp. Pathol. 8, 15177–15183. 26823863 Yan W. Gao X. Zhang S. (2017). Association of miR-196a2 rs11614913 and miR-499 rs3746444 polymorphisms with cancer risk: a meta-analysis. Oncotarget 8, 114344–114359. 10.18632/oncotarget.2254729371991 Yang H. Dinney C. P. Ye Y. Zhu Y. Grossman H. B. Wu X. (2008). Evaluation of genetic variants in microRNA-related genes and risk of bladder cancer. Cancer Res. 68, 2530–2537. 10.1158/0008-5472.CAN-07-599118381463 Yang H. Lu Q. L. Wu X. J. Ma H. Y. Qu Y. Y. Zhang D. Z. . (2016). Association of genetic variations in miR-146a rs2910164 and mir-149 rs11614913 with the development of classic Kaposi sarcoma. Genetics Mol. Res. 15:gmr.15048855. 10.4238/gmr1504885527819716 Yin Z. Cui Z. Guan P. Li X. Wu W. Ren Y. . (2015). Interaction between polymorphisms in pre-miRNA genes and cooking oil fume exposure on the risk of lung cancer in Chinese non-smoking female population. PLoS ONE 10:0128572. 10.1371/journal.pone.012857226083623 Yin Z. Cui Z. Ren Y. Xia L. Li H. Zhou B. (2017). MiR-196a2 and lung cancer in Chinese non-smoking females: a genetic association study and expression analysis. Oncotarget 8, 70890–70898. 10.18632/oncotarget.2017429050330 Yin Z. Cui Z. Ren Y. Xia L. Wang Q. Zhang Y. . (2016). Association between polymorphisms in pre-miRNA genes and risk of lung cancer in a Chinese non-smoking female population. Lung Cancer 94, 15–21. 10.1016/j.lungcan.2016.01.01326973201 Yoon K.-A. Yoon H. Park S. Jang H.-J. Zo J. I. Lee H.-S. . (2012). The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer. J. Thoracic Cardiovasc. Surg. 144, 794–807. 10.1016/j.jtcvs.2012.06.03022818121 Zhan J.-f. Chen L.-h. Chen Z.-x. Yuan Y.-w. Xie G.-z. Sun A.-m. . (2011). A Functional Variant in MicroRNA-196a2 Is Associated with Susceptibility of Colorectal Cancer in a Chinese Population. Arch. Med. Res. 42, 144–148. 10.1016/j.arcmed.2011.04.00121565628 Zhang E. Xu Z. Duan W. Huang S. Lu L. (2017). Association between polymorphisms in premiRNA genes & risk of oral squamous cell cancer in a Chinese population. PLoS ONE 12:0176044. 10.1371/journal.pone.017604428609461 Zhang H. Su Y.-L. Yu H. Qian B.-Y. (2012). Meta-Analysis of the Association between Mir-196a-2 Polymorphism and Cancer Susceptibility. Cancer Biol. Med. 9, 63–72. 10.3969/j.issn.2095-3941.2012.01.01223691458 Zhang H. Zhang Y. Yan W. Wang W. Zhao X. Ma X. . (2017). Association between three functional microRNA polymorphisms (miR-499 rs3746444, miR-196a rs11614913 and miR-146a rs2910164) and breast cancer risk: a meta-analysis. Oncotarget 8, 393–407. 10.18632/oncotarget.1342627880723 Zhang J. Wang R. Ma Y. Y. Chen L. Q. Jin B. H. Yu H. . (2013). Association between single nucleotide polymorphisms in miRNA196a-2 and miRNA146a and susceptibility to hepatocellular carcinoma in a Chinese population. Asian Pac. J. Cancer Prevent. 14, 6427–6431. 10.7314/APJCP.2013.14.11.642724377545 Zhang L. H. Hao B. B. Zhang C. Y. Dai X. Z. Zhang F. (2016). Contributions of polymorphisms in mir146a, mir196a, and mir499 to the development of hepatocellular carcinoma. Genet. Mol. Res. 15:gmr.15038582. 10.4238/gmr.1503858227706712 Zhang M. Jin M. Yu Y. Zhang S. Wu Y. Liu H. . (2012). Associations of miRNA polymorphisms and female physiological characteristics with breast cancer risk in Chinese population. Eur. J. Cancer Care 21, 274–280. 10.1111/j.1365-2354.2011.01308.x22074121 Zhang M. W. Jin M. J. Yu Y. X. Zhang S. C. Liu B. Jiang X. . (2012). Associations of lifestyle-related factors, hsa-miR-149 and hsa-miR-605 gene polymorphisms with gastrointestinal cancer risk. Mol. Carcinog 51(Suppl. 1), E21–31. 10.1002/mc.2086321976437 Zhao H. Xu J. Zhao D. Geng M. Ge H. Fu L. . (2016). Somatic Mutation of the SNP rs11614913 and Its Association with Increased MIR 196A2 Expression in Breast Cancer. DNA Cell Biol. 35, 81–87. 10.1089/dna.2014.278526710106 Zhou B. Dong L. P. Jing X. Y. Li J. S. Yang S. J. Wang J. P. . (2014). Association between miR-146aG>C and miR-196a2C>T polymorphisms and the risk of hepatocellular carcinoma in a Chinese population. Tumor Biol. 35, 7775–7780. 10.1007/s13277-014-2020-z24816919 Zhou B. Wang K. Wang Y. Xi M. Zhang Z. Song Y. . (2011). Common genetic polymorphisms in pre-microRNAs and risk of cervical squamous cell carcinoma. Mol. Carcinogenesis 50, 499–505. 10.1002/mc.2074021319225 Zhu L. Chu H. Gu D. Ma L. Shi D. Zhong D. . (2012). A functional polymorphism in miRNA-196a2 is associated with colorectal cancer risk in a Chinese population. DNA Cell Biol. 31, 349–353. 10.1089/dna.2011.134821815818 Zintzaras E. (2008). Variance estimation of allele-based odds ratio in the absence of Hardy-Weinberg equilibrium. Eur. J. Epidemiol. 23, 323–326. 10.1007/s10654-008-9242-618404407 Zintzaras E. Koufakis T. Ziakas P. D. Rodopoulou P. Giannouli S. Voulgarelis M. (2006). A meta-analysis of genotypes and haplotypes of methylenetetrahydrofolate reductase gene polymorphisms in acute lymphoblastic leukemia. Eur. J. Epidemiol. 21, 501–510. 10.1007/s10654-006-9027-816897583 Zintzaras E. Lau J. (2008). Synthesis of genetic association studies for pertinent gene-disease associations requires appropriate methodological and statistical approaches. J. Clin. Epidemiol. 61, 634–645. 10.1016/j.jclinepi.2007.12.01118538260 Abbreviations BC

breast cancer

 BlC

bladder cancer

 CRC

colorectal cancer

 ESCC

esophageal squamous cell carcinoma

 GC

gastric cancer

 GI

cancers of digestive system

 GyC

Gynecologic cancers

 HCC

Hepatocellular cancer

 HM

Hematological malignancies

 HNC

Head and neck carcinoma

 HWE

Hardy-Weinberg equilibrium

 HWD

Hardy-Weinberg deviation

 LC

lung cancer

 UG

Urogenital cancers

 OC

Oral cancer

 OR

Odds ratio

 OvC

ovarian cancer

 PC

prostate cancer.